



**HITACHI**

**GE Hitachi Nuclear Energy**

NEDO-34226

Revision C

July 2025

*US Protective Marking: Non-Proprietary Information  
UK Protective Marking: Not Protectively Marked*

# **BWRX-300 UK Generic Design Assessment (GDA) Chapter E9 - Prospective Radiological Assessment**

*Copyright 2025 GE-Hitachi Nuclear Energy Americas, LLC  
All Rights Reserved*

*US Protective Marking: Non-Proprietary Information  
UK Protective Marking: Not Protectively Marked*

NEDO-34226 Revision C

## **INFORMATION NOTICE**

This document does not contain proprietary information and carries the notations “US Protective Marking: Non-Proprietary Information” and “UK Protective Marking: Not Protectively Marked.”

## **IMPORTANT NOTICE REGARDING CONTENTS OF THIS REPORT**

### **Please Read Carefully**

The design, engineering, and other information contained in this document is furnished for the purpose of obtaining the applicable Nuclear Regulatory Authority review and determination of acceptability for use for the BWRX-300 design and licensing basis information contained herein. The only undertakings of GEH with respect to information in this document are contained in the contracts between GEH and its customers or participating utilities, and nothing contained in this document shall be construed as changing those contracts. The use of this information by anyone for any purpose other than that for which it is intended is not authorized; and with respect to any unauthorized use, no representation or warranty is provided, nor any assumption of liability is to be inferred as to the completeness, accuracy, or usefulness of the information contained in this document. Furnishing this document does not convey any license, express or implied, to use any patented invention or any proprietary information of GEH, its customers or other third parties disclosed herein or any right to publish the document without prior written permission of GEH, its customers or other third parties.

### **UK SENSITIVE NUCLEAR INFORMATION AND US EXPORT CONTROL INFORMATION**

This document does not contain any UK Sensitive Nuclear Information (SNI) subject to protection from public disclosure as described in the Nuclear Industries Security Regulations (NISR) 2003, does not contain UK Export Controlled Information (ECI), and does not contain US Export Controlled Information (ECI) subject to the export control laws and regulations of the United States, including 10 CFR Part 810.

## NEDO-34226 Revision C

### EXECUTIVE SUMMARY

The GE-Hitachi Nuclear Energy Americas, LLC (GEH) BWRX-300 is a Boiling Water Reactor (BWR) that is designed as a Small Modular Reactor (SMR).

This chapter is part of the Preliminary Environmental Report (PER) and is one of the documents that makes up the Environmental Case. It presents the results of the initial prospective radiological dose assessment of the predicted radiation doses to the public and to non-human species arising from exposure to ionising radiation due to planned discharges from the BWRX-300 to the atmosphere and to the aquatic environment. The contribution of direct dose has also been considered.

The dose assessment has been performed using the Environment Agency's (EA) "Initial Radiological Assessment Tool 2: Part 1 User Guide," (Reference 9-1) and "Initial Radiological Assessment Tool 2: Part 2 Methods and Input Data," (Reference 9-2). The discharge data used to perform the assessment are based on the annual average aqueous liquid and gaseous effluent activity releases derived by GEH for a BWRX-300 standard plant rather than the proposed discharge limits. These source terms are conservative and include contributions from Anticipated Operational Occurrences (AOO). Environmental information has been taken from NEDO-34219, "BWRX-300 UK GDA Chapter E2: Generic Site Description," (Reference 9-3). Where information or data are not yet available, a reasoned assumption has been made.

The initial prospective radiological dose assessment yields the following estimate:

1. An annual dose to the most exposed member of the public of 27.5  $\mu\text{Sv/y}$ , which is well below the source dose constraint of 300  $\mu\text{Sv/y}$  but slightly above the EA screening dose threshold of 20  $\mu\text{Sv/y}$ .
2. A dose rate to the most exposed non-human species of 4.3E-02  $\mu\text{Gy/h}$ , which is well below the EA screening dose rate of 1  $\mu\text{Gy/h}$  and the combined dose rate to habitats of 40  $\mu\text{Gy/h}$ .

These doses are the initial cautious screening outputs from Step 1 and Step 2 of the Generic Design Assessment (GDA). It is expected that there will be a reduction in the gaseous and aqueous liquid discharge activities once refined End User Source Terms and the aqueous liquid discharge volume are confirmed.

GEH considers that the radioactive discharge dose assessment presented fundamentally satisfies Step 2 of the GDA.

GEH has entered into the GDA process up to Step 2. Following GDA there will be a more realistic assessment of radiation doses associated with gaseous and aqueous liquid discharges using more sophisticated dose assessment tools and applying generic and (when available) site-specific habit data. A proposed outline methodology for this Stage 3 dose assessment is provided within this chapter and a Forward Action Plan is provided in Appendix B.

NEDO-34226 Revision C

## ACRONYMS AND ABBREVIATIONS

| Acronym  | Explanation   |
|----------|---|
| ABWR     | Advanced Boiling Water Reactor  |
| ADMS     | Atmospheric Dispersion Modeling Software                                  |
| ALARA    | As Low As Reasonably Achievable   |
| AOO      | Anticipated Occupational Occurrence                                       |
| BL3      | Baseline 3  |
| BAT      | Best Available Techniques   |
| BSSD     | Euratom Basic Safety Standards Directive                                  |
| BWR      | Boiling Water Reactor   |
| CEFAS    | Centre for Environment, Fisheries and Aquaculture Science                 |
| CERC     | Cambridge Environmental Research Consultants                              |
| CRP      | Candidate for the Representative Person                                   |
| DPUR     | Dose Per Unit Release   |
| EA       | Environment Agency  |
| EMCL     | Environmental Media Concentration Limits                                  |
| ENDP     | Engineering Developed Principles  |
| EPR16    | Environmental Permitting Regulations 2016                                 |
| ERICA    | Environmental Risks from Ionising Contaminants: assessment and management |
| EUST     | End User Source Terms   |
| FSA      | Food Standards Agency   |
| GALE     | Gaseous and Liquid Effluents  |
| GDA      | Generic Design Assessment   |
| GEH      | GE-Hitachi Nuclear Energy Americas, LLC                                   |
| HPA      | Health Protection Agency  |
| HSE      | Health and Safety Executive   |
| ICRP     | International Commission on Radiological Protection                       |
| IRAT2    | Initial Radiological Assessment Tool 2                                    |
| NDAWG    | National Dose Assessment Working Group                                    |
| NHS      | Non-Human Species   |
| NPP      | Nuclear Power Plant   |
| OPEX     | Operational Experience  |
| PC-CREAM | Consequences of Releases to the Environment Assessment Methodology        |
| PER      | Preliminary Environmental Report  |
| PSR      | Preliminary Safety Report   |
| PVS      | Plant Vent Stack  |
| RP       | Requesting Party  |
| RSMDP    | Radioactive Substances Management Developed Principles                    |

NEDO-34226 Revision C

| Acronym | Explanation                                  |
|---------|--|
| RSR     | Radioactive Substances Regulation            |
| SEDP    | Site Evaluation Generic Developed Principles |
| SMR     | Small Modular Reactor                        |
| TLD     | Thermoluminescent Detector                   |
| UK      | United Kingdom                               |
| UKHSA   | UK Health Security Agency                    |
| U.S.    | United States                                |
| USNRC   | U.S. Nuclear Regulatory Commission           |

NEDO-34226 Revision C

## DEFINITIONS AND SYMBOLS

| Term                  | Definition   |
|-----------------------|--|
| Collective dose       | The collective dose is the summated individual exposures to a population group from a specified source within a specified time period. The unit of collective dose is joule per kilogram and is referred to as man Sievert (Man Sv).   |
| Direct radiation      | Ionising radiation emitted directly by processes or operations on premises and not as a result of discharges of radioactive substances to the environment. Mostly consisting of gamma photons that are attenuated to varying degrees by distance or structures such as walls and other barriers. |
| Representative Person | An individual receiving a dose that is representative of the more highly exposed individuals in the population.  |

| Symbol            | Definition   |
|-------------------|--|
| Bq                | Becquerel (SI) unit of activity, defined as one decay per second.  |
| MBq               | 1.0E+06 Bq.  |
| Gy                | Gray (SI) unit of radiation dose, expressed as absorbed energy per unit mass of tissue. Does not describe the biological effects of different radiations. 1 Gy = 1 Joule/kilogram.   |
| μGy               | 1.0E-06 Gy.  |
| mGy               | 1.0E-03 Gy.  |
| m <sup>3</sup> /s | Cubic metres per second.   |
| m <sup>3</sup> /y | Cubic metres per year.   |
| R                 | Roentgen (legacy) unit of measurement for the exposure of X-rays and gamma rays, where 1 R = 0.000258 coulombs per kilogram (C/kilogram) of air.   |
| mR                | 1.0E-03 R.   |
| rem               | Roentgen equivalent man (centimetre-gram-second) unit of radiation dose which represents the stochastic health risks of radiation, by applying radiation weighting factors and tissue weighting factors. 1 rem is equivalent to 0.01 Sv. |
| mrem              | 1.0E-03 rem.   |
| Std. qtr          | Standard quarter year, ~ 90 days.  |
| Sv                | Sievert, (SI) unit of radiation dose which represents the stochastic health risks of radiation, by applying radiation weighting factors and tissue weighting factors. 1 Sv = 1 joule/kilogram (biological effect).                       |
| μSv               | 1.0E-06 Sv.  |
| μSv/h             | Rate at which the radiation dose is delivered per hour.  |
| mSv               | 1.0E-03 Sv.  |

NEDO-34226 Revision C

**TABLE OF CONTENTS**

|  |            |
|--|------------|
| <b>EXECUTIVE SUMMARY .....</b>   | <b>iii</b> |
| <b>ACRONYMS AND ABBREVIATIONS .....</b>  | <b>iv</b>  |
| <b>DEFINITIONS AND SYMBOLS .....</b>   | <b>vi</b>  |
| <b>9 PROSPECTIVE RADIOLOGICAL ASSESSMENT .....</b>   | <b>1</b>   |
| 9.1 Regulatory Context .....   | 4          |
| 9.1.1 Legislative Framework .....  | 4          |
| 9.1.2 United Kingdom Legislative Requirements .....  | 4          |
| 9.1.3 Radioactive Substances Guidance .....  | 6          |
| 9.2 Dose Assessment .....  | 7          |
| 9.2.1 Regulatory Requirements .....  | 7          |
| 9.2.2 Dose Assessment Approach .....   | 7          |
| 9.2.3 Selection and Suitability of the IRAT2 Dose Assessment Tool .....  | 8          |
| 9.3 Radiological Assessment Data Inputs .....  | 10         |
| 9.3.1 Generic Site Description .....   | 10         |
| 9.3.2 Liquid and Gaseous Discharge Source Terms .....  | 10         |
| 9.3.3 Direct Radiation .....   | 10         |
| 9.3.4 Stage 1 Assessment Methodology .....   | 11         |
| 9.3.5 Stage 2 Assessment Methodology .....   | 13         |
| 9.4 Dose Assessment Results and Discussion .....   | 15         |
| 9.4.1 Stage 1 Assessment .....   | 15         |
| 9.4.2 Stage 2 Assessment .....   | 15         |
| 9.4.3 Conclusion .....   | 17         |
| 9.5 Proposed Methodology for Stage 3 Assessment of Radiation Doses due to<br>Continuous Liquid and Gaseous Discharge ..... | 18         |
| 9.5.1 Introduction .....   | 18         |
| 9.5.2 BWRX-300 Source Term .....   | 18         |
| 9.5.3 Dose Assessment Modelling .....  | 19         |
| 9.5.4 Dispersion Modelling .....   | 19         |
| 9.5.5 Exposure Pathways .....  | 22         |
| 9.5.6 Habit Data .....   | 23         |
| 9.5.7 Candidates for the Representative Person .....   | 24         |
| 9.5.8 Individual Dose Assessment for the CRPs .....  | 25         |
| 9.5.9 Collective Dose Assessment .....   | 26         |
| 9.5.10 Build-Up Dose Assessment .....  | 26         |
| 9.5.11 Short-Term Dose Assessment .....  | 27         |
| 9.5.12 Dose Assessment for Non-Human Species .....   | 28         |
| 9.5.13 Uncertainty Assessment .....  | 29         |

NEDO-34226 Revision C

9.6 Conclusion ..... 31

9.7 References..... 54

**APPENDIX A      IRAT2 Outputs..... 59**

**APPENDIX B      Forward Action Plan ..... 75**



NEDO-34226 Revision C

## LIST OF TABLES

|   |           |
|---|-----------|
| <b>Table 9-1: BWRX-300 Annual Average Liquid Effluent Activity Releases.....</b>  | <b>32</b> |
| <b>Table 9-2: BWRX-300 Annual Average Gaseous Effluent Activity Releases .....</b>  | <b>33</b> |
| <b>Table 9-3: Summary of Operational BWR Reported TLD Data from the 2023 USNRC<br/>Environmental Reports .....</b>                              | <b>34</b> |
| <b>Table 9-4: Sites Potentially Suitable for Deployment of a New Nuclear Power Station<br/>and Their Coastal Exchange Rate .....</b>            | <b>35</b> |
| <b>Table 9-5: Liquid Discharge: Radionuclides Without a DPUR, Origin and Proposed<br/>Surrogate .....</b>                                       | <b>36</b> |
| <b>Table 9-6: Liquid Discharge: Radionuclides Without a DPUR, Categories for Stage 2<br/>IRAT2 Modelling .....</b>                              | <b>37</b> |
| <b>Table 9-7: Gaseous Discharge: Radionuclides Without a DPUR, Origin and Proposed<br/>Surrogate .....</b>                                      | <b>38</b> |
| <b>Table 9-8: Gaseous Discharge: Radionuclides Without a DPUR, Categories for Stage 2<br/>IRAT2 Modelling .....</b>                             | <b>39</b> |
| <b>Table 9-9: Estimated Stage 1 Dose to the Representative Person (Liquid Discharge) 40</b>   |           |
| <b>Table 9-10: Breakdown of Stage 1 Scenario 2 Dose to the Representative Person by<br/>Radionuclide (Liquid Discharge).....</b>                | <b>41</b> |
| <b>Table 9-11: Breakdown of Stage 1 Scenario 3 Dose to the Representative Person by<br/>Radionuclide (Liquid Discharge).....</b>                | <b>42</b> |
| <b>Table 9-12: Estimated Stage 1 Dose to the Representative Person (Gaseous<br/>Discharge).....</b>   | <b>43</b> |
| <b>Table 9-13: Breakdown of Stage 1 Dose to the Representative Person by Radionuclide<br/>(Gaseous Discharge – Noble Gases as Xe-133) .....</b> | <b>44</b> |
| <b>Table 9-14: Breakdown of Stage 1 Dose to the Representative Person by Radionuclide<br/>(Gaseous Discharge – Noble Gases as Kr-88) .....</b>  | <b>45</b> |
| <b>Table 9-15: Stage 1 Assessment – Total Dose to the Representative Person .....</b>   | <b>46</b> |
| <b>Table 9-16: Estimated Stage 2 Dose to the Representative Person (Liquid Discharge)<br/>.....</b>   | <b>47</b> |
| <b>Table 9-17: Breakdown of Stage 2 Scenario 2 Dose to the Representative Person by<br/>Radionuclide (Liquid Discharge).....</b>                | <b>48</b> |
| <b>Table 9-18: Breakdown of Stage 2 Scenario 3 Dose to the Representative Person by<br/>Radionuclide (Liquid Discharge).....</b>                | <b>49</b> |
| <b>Table 9-19: Estimated Stage 2 Dose to the Representative Person (Gaseous<br/>Discharge).....</b>   | <b>50</b> |
| <b>Table 9-20: Breakdown of Stage 2 Dose to the Representative Person by Radionuclide<br/>(Gaseous Discharge – Noble Gases as Xe-133) .....</b> | <b>51</b> |
| <b>Table 9-21: Breakdown of Stage 2 Dose to the Representative Person by Radionuclide<br/>(Gaseous Discharge – Noble Gases as Kr-88) .....</b>  | <b>52</b> |
| <b>Table 9-22: Stage 2 Assessment – Total Dose to the Representative Person .....</b>   | <b>53</b> |
| <b>Table A-1: Estimated Stage 1 Dose to the Representative Person (Liquid Discharge,<br/>Bounding Case Scenario 2) .....</b>                    | <b>59</b> |
| <b>Table A-2: Estimated Stage 1 Dose to Wildlife (Liquid Discharge, Bounding Case<br/>Scenario 2) .....</b>                                     | <b>60</b> |

NEDO-34226 Revision C

|  |           |
|--|-----------|
| <b>Table A-3: Estimated Stage 1 Dose to the Representative Person (Gaseous Discharge, Noble Gases Modelled as Xe-133).....</b> | <b>61</b> |
| <b>Table A-4: Estimated Stage 1 Dose to the Representative Person (Gaseous Discharge, Noble Gases Modelled as Kr-88) .....</b> | <b>63</b> |
| <b>Table A-5: Estimated Stage 1 Dose to Wildlife (Gaseous Discharge, Noble Gases Modelled as Xe-133) .....</b>                 | <b>65</b> |
| <b>Table A-6: Estimated Stage 2 Dose to the Representative Person (Liquid Discharge, Bounding Case Scenario 2) .....</b>       | <b>67</b> |
| <b>Table A-7: Estimated Stage 2 Dose to Wildlife (Liquid Discharge, Bounding Case Scenario 2) .....</b>                        | <b>68</b> |
| <b>Table A-8: Estimated Stage 2 Dose to the Representative Person (Gaseous Discharge, Noble Gases Modelled as Xe-133).....</b> | <b>69</b> |
| <b>Table A-9: Estimated Stage 2 Dose to the Representative Person (Gaseous Discharge, Noble Gases Modelled as Kr-88) .....</b> | <b>71</b> |
| <b>Table A-10: Estimated Stage 2 Dose to Wildlife (Gaseous Discharge, Noble Gases Modelled as Xe-133) .....</b>                | <b>73</b> |
| <b>Table B-1: Forward Action Plan .....</b>  | <b>75</b> |

NEDO-34226 Revision C

## **LIST OF FIGURES**

None.

NEDO-34226 Revision C

**REVISION SUMMARY**

| <b>Revision #</b> | <b>Section Modified</b> | <b>Revision Summary</b>                    |
|-------------------|-------------------------|--|
| A                 | All                     | Initial Issuance                           |
| B                 | References/hyperlinks   | Editorial update to references             |
| C                 | All                     | Update for end of GDA Step 2 consolidation |

NEDO-34226 Revision C

## 9 PROSPECTIVE RADIOLOGICAL ASSESSMENT

### Introduction

The BWRX-300 Small Modular Reactor (SMR) is the tenth iteration of the Boiling Water Reactor (BWR) design, as denoted by the letter X. The BWRX-300 is a 300 MW(e) reactor design based on, and very similar to, predecessor BWRs including the Advanced Boiling Water Reactor (ABWR) and the Economic Simplified Boiling Water Reactor. The ABWR successfully completed Generic Design Assessment (GDA) in the United Kingdom (UK) in 2017 and received regulatory approval in the form of a Design Acceptance Confirmation from the Office for Nuclear Regulation and a Statement of Design Acceptability from the Environment Agency (EA).

Routine operation of the BWRX-300 has the potential to impact the surrounding environment due to the emission of radionuclides generated in the reactor, either as aqueous liquid (henceforth referred to as liquid) or gaseous discharges.

This chapter forms part of the Preliminary Environmental Report (PER) for the BWRX-300. It presents the methodology, parameters, and results of calculations undertaken to determine the effect that routine radioactive liquid and gaseous discharges may have on the surrounding human population and Non-Human Species (NHS) during normal operation of the BWRX-300 SMR at a generic coastal site.

The overall objective of the PER is to demonstrate that the design of the BWRX-300 has been optimised to reduce environmental impacts to As Low As Reasonably Achievable (ALARA) throughout the whole lifecycle (construction, commissioning, operation, and decommissioning), where ALARA is a radiation protection principle that everything reasonably possible should be done to reduce radiation exposure.

This chapter supports the overall environmental claim that:

- The BWRX-300 is capable of being constructed, operated, and decommissioned in accordance with the standards of environmental, safety, security, and safeguard protection required in the UK.

The environmental Level 1 claim is:

- The design of the BWRX-300 SMR has been optimised to reduce environmental impacts via application of ALARA principles throughout the whole lifecycle (construction, commissioning, operation, and decommissioning).

The environmental Level 2 claim applicable to this report is:

- Minimisation of the impact of radioactive discharges on members of the public and the environment.

The environmental claims for the BWRX-300 are discussed in more detail in NEDO-34223, "BWRX-300 UK GDA Chapter E6: Demonstration of Best Available Techniques (BAT) Approach," (Reference 9-4).

### Scope

The GEH BWRX-300 Nuclear Power Plant (NPP) design has entered into GDA with the objective to gain regulatory confidence on the acceptability of a conceptual full plant design through Steps 1 and 2 of GDA, "New Nuclear Power Plants: Generic Design Assessment Guidance for Requesting Parties," (Reference 9-5). This approach is used when the design and substantiation are not yet mature enough to complete a detailed assessment. This document is one part of the suite of documents required for GDA and is part of the environmental case submission.

## NEDO-34226 Revision C

This chapter provides a radiological impact assessment of the radiation dose due to offsite liquid and gaseous discharges from a BWRX-300 SMR to members of the public and NHS during normal operations.

The assessment also includes consideration of the contribution from direct dose which has been based upon a review of Operational Experience (OPEX) for BWR NPPs in the United States (U.S.). This direct dose has been added to the doses calculated for liquid and gaseous discharges to estimate the total dose from the BWRX-300.

It is noted that the BWRX-300 is designed such that it can be operated with a maximum recirculation philosophy, 007N1460, "BWRX-300 Annual Average Liquid Effluent Activity Releases," (Reference 9-6), with liquid wastes being managed by the Liquid Waste Management System; however, in the event that a liquid discharge is required then this will be made from the Circulating Water System.

The BWRX-300 gaseous discharges are associated with the Off-Gas System and the Heating, Ventilation, and Cooling System. The Off-Gas System and Heating, Ventilation, and Cooling System discharge into the Continuous Exhaust Air Plenum. The Continuous Exhaust Air Plenum serves as a large mixing box where potentially contaminated air is mixed and diluted before it is discharged to atmosphere via the Plant Vent Stack (PVS), NEDO-34224, "BWRX - 300 UK GDA Chapter E7: Radioactive Discharges," (Reference 9-7).

The items listed below have been excluded from the Step 1 and Step 2 GDA radiological impact assessment. However, the proposed methodology for assessing the dose contributions at a later stage in the GDA process for collective dose, build-up and short-term dose is provided within this chapter.

- Collective dose truncated at 500 years to the UK, European, and world populations.
- An assessment of whether the build-up of radionuclides in the local environment of the facility, based on the anticipated lifetime discharges, might have the potential to prejudice the activities of other legitimate users or uses of the land or sea.
- Potential short-term doses, including via the food chain, based on the maximum anticipated short-term discharges from the facility in normal operation.
- Doses due to discharges associated with accidents or fault conditions (noting that contributions from Anticipated Occupational Occurrence (AOO) are included in the annual average gaseous and liquid discharge source terms that have been assessed).
- Doses due to discharges arising from the construction phase or the decommissioning phase.
- Doses due to disposal of radioactive waste to offsite waste facilities in accordance with "The Environmental Permitting (England and Wales) Regulations 2016," (EPR16) (Reference 9-8) site permit.

Occupational doses to workers are considered in NEDO-34175, "BWRX-300 UK GDA Chapter 12: Radiation Protection," (Reference 9-9).

### Document Structure

This PER chapter is divided into the following sections:

- Section 9.1 – Regulatory context: discusses the legislative framework, screening thresholds, dose limits and dose constraints, and radioactive substances guidance within the UK.
- Section 9.2 – Dose assessment: discusses the regulatory requirements for dose assessment, the three-stage process, and suitability of the proposed assessment tool.

## NEDO-34226 Revision C

- Section 9.3 – Radiological assessment data inputs: provides the assumptions for the generic site, the liquid discharge and gaseous discharge source terms, the approach taken for direct radiation, and outlines the Stage 1 and Stage 2 dose assessment methodology.
- Section 9.4 – Dose assessment results and discussion: presents the results for the Stage 1 and Stage 2 dose assessments for liquid and gaseous discharges, and the Stage 1 and Stage 2 dose assessment to the representative person and wildlife.
- Section 9.5 – Stage 3 dose assessment methodology: presents the proposed methodology for the Stage 3 dose assessment, considering the source term, dispersion modelling to the marine and terrestrial environments, exposure pathways, habit data, candidates for the representative person, individual and collective dose assessment, build up dose assessment, short-term release dose assessment, and consideration of dose assessment uncertainties.
- Section 9.6 – Conclusion: summary of the Stage 1 and Stage 2 dose assessment.
- Section 9.7 – References: a list of the supporting references used in this chapter.

Further information of relevance to this chapter is provided in the Appendices:

- Appendix A: Initial Radiological Assessment Tool (IRAT2) outputs
- Appendix B: Forward Action Plan

### **Interfaces with other Chapters**

This chapter interfaces with, and references data and information from, the following:

- PER Chapter E2 (Reference 9-3)
- PER Chapter E6 (Reference 9-4)
- PER Chapter E7 (Reference 9-7)

This chapter also interfaces with the BWRX-300 UK GDA Preliminary Safety Report (PSR), especially:

- PSR Chapter 12 (Reference 9-9)

## NEDO-34226 Revision C

### 9.1 Regulatory Context

#### 9.1.1 Legislative Framework

The legislative framework for radiological protection in the UK is derived from the International Commission on Radiological Protection's (ICRP) recommendations, first in the implementation of the 1990 recommendations, "1990 Recommendations of the International Commission on Radiological Protection," (Reference 9-10) as part of the 1996 Euratom Basic Safety Standards Directive (BSSD), "Council Directive 96/29/Euratom of 13 May 1996 Laying Down Basic Safety Standards for the Protection of the Health of Workers and the General Public Against the Dangers Arising from Ionizing Radiation," (Reference 9-11) within the European Union, and later revised in 2013 to address the 2007 Recommendations of the ICRP, "The 2007 Recommendations of the International Commission on Radiological Protection," (Reference 9-12). This new BSSD (Council Directive 2013/59/Euratom of 5 December 2013), "Council Directive 2013/59/Euratom of 5 December 2013 Laying Down Basic Safety Standards for Protection Against the Dangers Arising From Exposure To Ionising Radiation, and Repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom," (Reference 9-13) was adopted in 2014 and had to be enacted into national legislation of EU member states by February 2018.

In the UK, BSSD has been incorporated into legislation through several regulations to ensure the UK's regulations align with European standards for radiological protection, including the 2017 Ionising Radiations Regulations, "The Ionising Radiations Regulations 2017," (Reference 9-14) and, with respect to the control of radioactive waste, through EPR16 (Reference 9-8) for England and Wales, The Environmental Authorisations (Scotland) Regulations 2018 (EA(S)R) in Scotland, "The Environmental Authorisations (Scotland) Regulations 2018," (Reference 9-15), and The Radioactive Substances (Modification of Enactments) Regulations (Northern Ireland), "The Radioactive Substances (Modification of Enactments) Regulations (Northern Ireland) 2018," (Reference 9-16).

#### 9.1.2 United Kingdom Legislative Requirements

##### 9.1.2.1 Basic Safety Standards Directive

Article 12 of the BSSD (Reference 9-13) sets a limit on the effective dose for public exposure at 1 mSv/y, and Article 66 of the BSSD (Reference 9-13) requires that Member States ensure that arrangements are made for the estimation of doses to members of the public from authorised practices, and requires that this dose assessment must be carried out in a realistic way.

##### 9.1.2.2 Environmental Permitting Regulations

Schedule 23 part 4 of EPR16 (Reference 9-8) confirms the requirements for exposures and doses relating to radioactive waste discharges to the environment.

Optimisation and dose limits:

- In respect of a radioactive substances activity that relates to radioactive waste, the regulator must exercise its relevant functions to ensure that:
  - All exposures to ionising radiation of any member of the public and of the population as a whole resulting from the disposal of radioactive waste are kept ALARA, taking into account economic and social factors, and
  - The sum of the doses resulting from the exposure of any member of the public to ionising radiation does not exceed the dose limits set out in Article 13 of the Basic Safety Standards Directive subject to the exclusions set out in Article 6(4) of that Directive.



## NEDO-34226 Revision C

Specific dose limits:

- In exercising those relevant functions in relation to the planning stage of radiation protection, the regulator must have regard to the following maximum doses to individuals which may result from a defined source:
  - 0.3 millisieverts per year from any source from which radioactive discharges are first made on or after 13th May 2000, or
  - 0.5 millisieverts per year from the discharges from any single site.

### **9.1.2.3 Application of the 2007 Recommendations of the ICRP to the United Kingdom**

For planned exposure situations relating to new NPPs and new waste disposal facilities, the Health Protection Agency (HPA) (now known as the UK Health Security Agency (UKHSA)) advised the UK Government to adopt a lower dose constraint of 0.15 mSv per year to take into account uncertainties in the understanding of some health effects and the possibility that judgements on radiation risks might change within the timescale of planning and constructing a new NPP, RCE-12, "Application of the 2007 Recommendations of the ICRP to the UK," (Reference 9-17). However, this advice has not become formal guidance.

### **9.1.2.4 Other Guidance**

In 1995, a review of the UK radioactive waste policy, CM2919, "Review of Radioactive Waste Management Policy Final Conclusions," (Reference 9-18) set a threshold of 0.02 mSv/y as being broadly and cautiously equivalent to an annual risk of death of 1 in 1.0E+06, considering this to be a lower-bound optimisation consistent with the general practices of the Health and Safety Executive (HSE).

The UK Environment Agencies (EA, Scottish Environment Protection Agency, Northern Ireland Environment Agency) have worked with UKHSA and the Food Standards Agency (FSA) to produce guidance on the "Principles for Assessment of Prospective Public Doses from Discharges of Radioactive Waste to the Environment," (Reference 9-19). This is a key reference document which recommends taking a staged approach to prospective dose assessments, also referencing a screening dose threshold of 0.02 mSv.

A lower threshold for the most exposed members of the public of 10  $\mu$ Sv/y was advised under EPR, "Criteria for Setting Limits on the Discharge of Radioactive Waste from Nuclear Sites," (Reference 9-20) below which the EA should not seek to further reduce the discharge limits that are in place, provided that the holder of the permit continues to apply BAT. Although it is noted that the BWRX-300 is being designed such that the dose target for critical receptors/members of the public during normal operations should be a fraction of <10  $\mu$ Sv/year as stated in 006N5081, "BWRX-300 As Low as Reasonably Achievable Design Criteria for Standard Design," (Reference 9-21), this design target relates to liquid and gaseous discharges from a single unit only, and so the design criteria of 10  $\mu$ Sv/y does not align with the EA's lower threshold of 10  $\mu$ Sv/y which would also include the contribution from direct dose.

### **9.1.2.5 Non-Human Species**

For non-human species, ICRP recommendations (Reference 9-12) detail that during planned, existing, and emergency situations, all of the environment needs to be considered, including areas where humans are absent. The aims of environmental radiation protection are focused on preventing or reducing the frequency of radiation effects to a level where they would have a negligible impact on the maintenance of biological diversity, the conservation of species, or the health and status of natural habitats, communities, and ecosystems.

## NEDO-34226 Revision C

The EA, Natural England, and the Countryside Council for Wales have agreed a dose rate threshold of 40  $\mu\text{Gy/h}$ , SC060083/SR1, “Habitats assessment for radioactive substances,” (Reference 9-22), below which it has been concluded that there will be no adverse effect on the integrity of a Natura 2000 site (a European protected area covering valuable and threatened species and habitats). It is also a requirement of the environmental permit application for a nuclear site that there is an assessment of the impact of radioactive discharges on non-human species EPG-RSR-B3, “How to apply for an environmental permit Part RSR-3 – New bespoke radioactive substances activity permit nuclear site – unsealed sources and radioactive waste,” (Reference 9-23), with this assessment being applicable to the setting of site limits for specific radionuclides (Reference 9-20). For the purpose of the prospective dose assessment, a more restrictive dose rate threshold of 1  $\mu\text{Gy/h}$  is applied (Reference 9-1), (Reference 9-2).

### 9.1.3 Radioactive Substances Guidance

The EA has published a suite of guidance documentation relating to regulation of activities involving radioactive substances, and the principles that are applied. The EA Radioactive Substances Regulation (RSR) objective and principles, “Radioactive substances regulation (RSR): objective and principles,” (Reference 9-24) states an objective to protect people and the environment from the harmful effects of ionising radiation by applying relevant legislation, government policy, and international standards.

The EA RSR Generic Developed Principles, “RSR generic developed principles: regulatory assessment,” (Reference 9-25) detail the generic developed principles on regulatory assessment for radioactive substances activities, divided into eight sections. The relevant ‘Radioactive Substances Management Developed Principles’ (RSMDPs), Site Evaluation Generic Developed Principles (SEDPs) and Engineering Developed Principles (ENDPs) considered to be most relevant to a prospective dose assessment for members of the public and wildlife are:

- RSMDP12 – Limits and levels should be established on the quantities of radioactivity that can be discharged into the environment where these are necessary to secure proper protection of human health and the environment.
- RPDP1 – All exposures to ionising radiation of any member of the public and of the population as a whole shall be kept ALARA, economic and social factors being taken into account.
- RPDP2 – Radiation doses to individual people shall be below the relevant dose limits and in general should be below the relevant constraints.
- RPDP3 – Non-human species should be adequately protected from exposure to ionising radiation.
- RPDP4 – Assessments of potential doses to people and to non-human species should be made prior to granting any new or revised permit for the discharge of radioactive wastes into the environment.
- SEDP1 – When evaluating sites for a new facility, account should be taken of the factors that might affect the protection of people and the environment from radiological hazards and the generation of radioactive waste.
- SEDP2 – Data should be provided to allow the assessment of rates and patterns of migration of radioactive materials in the air and the aquatic and terrestrial environments around sites.
- ENDP1 – The underpinning environmental aim for any facility should be that the design inherently protects people and the environment, consistent with the operational purpose of the facility.

## NEDO-34226 Revision C

### 9.2 Dose Assessment

#### 9.2.1 Regulatory Requirements

The GDA guidance for Requesting Parties (Reference 9-5) outlines a three-step process:

- Step 1: Initiation
- Step 2: Fundamental Assessment
- Step 3: Detailed Assessment

The guidance also specifies the requirements for a prospective dose assessment, stating that the Requesting Party (RP) must provide a radiological assessment of proposed limits for:

- Annual dose to most exposed members of the public for liquid discharges\*
- Annual dose to most exposed members of the public for gaseous discharges (separately identify the dose associated with on-site incineration where applicable)\*
- Annual dose to the most exposed members of the public for all discharges from the facility\*
- Annual dose from direct radiation to the most exposed members of the public

The RP must also provide:

- Annual dose to the representative person for the facility
- Potential short-term doses, including via the food chain, based on the maximum anticipated short-term discharges from the facility in normal operation
- A comparison of the calculated doses with the relevant dose constraints
- An assessment of whether the build-up of radionuclides in the local environment of the facility, based on the anticipated lifetime discharges, might have the potential to prejudice the activities of other legitimate users or uses of the land or sea
- Collective dose truncated at 500 years to the UK, European and world populations
- Dose-rate to NHS\*

The RP must state which models they have used to calculate these doses and why the models are appropriate. They must set out all the data and assumptions they have used as input to the models, together with reasoning as to why these assumptions are appropriate.

For items marked with an asterisk (\*), the guidance recommends that the RP uses the EA's IRAT2 (Reference 9-1, Reference 9-2), refining the default data to reflect the characteristics of the facility and generic site.

The BWRX-300 dose assessment presented in this chapter is for Step 1 and Step 2 only and does not include a more realistic dose assessment which would be undertaken at Step 3. GDA guidance to the requesting parties (Reference 9-5) does not specify as to which of the above listed dose estimations must be included in the Step 2 assessment, but EA guidance (Reference 9-19) lists evaluation of short-term release and collective dose under the detailed source and site assessment (Step 3), along with comparison of doses to the source constraint, site constraint and dose limits.

#### 9.2.2 Dose Assessment Approach

Guidance on the principles for assessment of prospective public doses from radioactive waste discharges to the environment (Reference 9-19) recommends taking a staged approach to dose assessments, comprising an initial cautious assessment of dose using a screening threshold of 0.02 mSv followed by a more detailed and realistic assessment using site specific

## NEDO-34226 Revision C

information (when available). This staged approach is also advised by the National Dose Assessment Working Group (NDAWG) in their guidance note, "Guidance on initial/simple assessment tools," (Reference 9-26), which also identifies a number of simple radiological assessment tools suitable for the initial radiological assessment, including the EA's IRAT2 methodology (Reference 9-1, Reference 9-2).

The staged approach can be broken down as follows:

- Stage 1: an initial cautious assessment for routine discharges using conservative default data and generic assumptions about the site and the representative person, multiplying Dose Per Unit Release (DPUR) values by the radioactive discharge activities. This can be achieved using the EA's IRAT2 (Reference 9-1, Reference 9-2) spreadsheets which are available by request, LIT 15793, "Initial radiological assessment tool - estuary\_coast," (Reference 9-27) and LIT 15791, "Initial radiological assessment tool – air," (Reference 9-28). The IRAT2 spreadsheets can also be used to calculate the dose rate to the worst-affected wildlife group using the same inputs.
- Stage 2: the Stage 1 screening dose assessment is refined by adjusting some of the default parameters to more realistic ones. This is largely achieved by scaling the dose to take account of the dispersion conditions, for example, modifying the volumetric exchange rate for liquid discharges and using a more realistic release height for gaseous discharges.
- Stage 3: the dose assessment is now refined to reflect more realistic parameters using site-specific data where available, such as the volumetric exchange rate, the release height, meteorological conditions and receptor points, and habit data. At this more detailed assessment stage, in addition to routine discharges, there is also consideration of contribution to dose from a short-term discharge, from build-up of radionuclides in the marine and terrestrial environment (for example Bq/L in seawater, and Bq/kg in seabed sediment and soil after 60 years of continuous operation), and of both individual and collective doses to members of the public.

The Stage 1 screening dose assessment aligns with GDA Step 1, and the Stage 2 refined screening dose assessment aligns with GDA Step 2. The Stage 3 more realistic dose assessment aligns with GDA Step 3. It is noted that GEH has entered into the GDA process up to Step 2 only.

EA guidance (Reference 9-19) states that a Stage 3 assessment is not usually required for most non-nuclear premises if the Stage 1 and Stage 2 doses are below the threshold of 0.02 mSv/y, however a Stage 3 assessment is required at a later date in support of environmental permitting applications.

### 9.2.3 Selection and Suitability of the IRAT2 Dose Assessment Tool

The IRAT2 methodology has been selected as the radiological assessment tool in-line with recommended UK guidance from the EA (Reference 9-5) and NDAWG (Reference 9-26). The IRAT2 is considered to be suitable as it allows a cautious assessment for the release of over 100 radionuclides to air and coastal/estuary waters. The tool is supported by four spreadsheets (Initial radiological assessment tool - estuary\_coast (Reference 9-27), Initial radiological assessment tool – air (Reference 9-28), LIT 15792, "Initial radiological assessment tool – river," (Reference 9-29), LIT 15794, "Initial radiological assessment tool – sewer," (Reference 9-30)) which calculate doses for different release routes, exposure groups, and different age groups (offspring, infant, child, adult), and the dose rates to wildlife. Each spreadsheet provides the total dose to the worst affected population exposure group, the contribution to the dose from food pathways, and the dose rate to the worst affected reference organism. The most recent IRAT2 version of the spreadsheets have been used, as provided

## NEDO-34226 Revision C

by the EA (Initial radiological assessment tool - estuary\_coast (Reference 9-27), Initial radiological assessment tool – air (Reference 9-28)).

Comparison to other dose assessment tools (Reference 9-26) confirms that they are broadly equivalent for a ground-level release to air provided the same assumptions are used. In addition, IRAT2 also offers the flexibility to vary release height. For release to estuary/coastal waters, the IRAT2 tool accounts for radioactive decay and thus does not over-estimate doses in this respect.

## NEDO-34226 Revision C

### 9.3 Radiological Assessment Data Inputs

#### 9.3.1 Generic Site Description

The generic site for the BWRX-300 does not represent any particular location in the UK but represents the envelope of the potential UK site conditions potentially suitable for the deployment of new nuclear power stations by the end of 2025. It is described in PER Chapter E2 (Reference 9-3).

The main assumptions about the Generic Site relevant to the radiological dose assessment are:

- The BWRX-300 is a single unit of 300 MW(e) capacity
- The site is coastal; radioactive liquid discharges will be made to the marine or estuarine environments
- There are no radioactive liquid discharges to river
- There are no radioactive liquid discharges to groundwater
- There are no radioactive liquid discharges to the sewage network
- Gaseous discharges are made through the PVS
- There is no radioactive gaseous discharge via incineration
- The site and its surrounding area are assumed to lie on a flat plain with no other large buildings in the immediate vicinity. The effects of neighboring buildings and local terrain on the gaseous discharge will not be considered until the site-specific permitting stage.

#### 9.3.2 Liquid and Gaseous Discharge Source Terms

The Stage 1 and Stage 2 dose assessments have been performed using the BWRX-300 Annual Average Liquid Effluent Activity Releases (Reference 9-6) and 007N1078 "Annual Average Gaseous Effluent Releases for the BWRX-300 Standard Plant," (Reference 9-31), which includes AOOs. How the liquid and gaseous effluent activities have been calculated is described in detail in the corresponding references.

PER Chapter E7 (Reference 9-7) Section 7.2 discusses how the annual average discharge source terms have been developed using the Gaseous and Liquid Effluents (GALE), GALE-BWR, methodology in NUREG-0016, "Calculation of Release of Radioactive Materials in Gaseous and Liquid Effluents from Boiling-Water Reactors: GALE-BWR 3.2 Code," (Reference 9-32). As described in PER Chapter E7, these discharge activities are considered to be conservative and bounding and are comparable to those associated with other relevant international plants. For this reason, a headroom factor has not been included at Step 2 of the GDA to avoid adding further conservatism.

The annual average liquid discharge is presented in Table 9-1 and the annual average gaseous release is presented in Table 9-2. The liquid release activities in Table 9-1 are assumed to correspond to a maximum release volume of 5,968 m<sup>3</sup>/y based on the low purity waste input stated in Table 4-1 of BWRX-300 Annual Average Liquid Effluent Activity Releases (Reference 9-6).

#### 9.3.3 Direct Radiation

At GDA Step 2, there has not yet been any assessment of potential dose-rates at the site perimeter due to direct radiation from the various BWRX-300 facilities. These dose rates will be modelled at a later stage in the assessment process using an industry standard shielding code and considering facility source terms and defined receptor distances.



## NEDO-34226 Revision C

To allow consideration of the contribution from direct dose to a member of the public during the Step 1 and Step 2 dose assessment, Operating Experience (OPEX) from 20 operational BWRs in the U.S. has been used that captures environmental monitoring data associated with the use of Thermoluminescent Detectors (TLDs) at the site boundary, as reported in U.S. Nuclear Regulatory Commission (USNRC) environmental reports, "Radioactive Effluent and Environmental Reports," (Reference 9-33). Where a dose range was provided (dose per year, dose per quarter, dose per month or dose per day) the maximum dose value was used to calculate the estimated annual dose for each station, and an average then taken of these values as shown in Table 9-3. It is noted that the layout of the U.S. BWR sites with respect to locations of TLD monitoring stations and their proximity to direct radiation sources (radioactive waste stores etc.) is unknown, and that the power capacity of the operational BWR sites is significantly higher than for the BWRX-300 which is expected to result in a higher radioactive waste inventory.

For the assessment of doses due to gaseous discharges, the IRAT2 tool assumes that the local resident is located 100 m from the release point and that the food production location is 500 m from the release point, a very cautious assumption that is considered appropriate for the initial first assessment stage. However, for the direct dose assessment, it is considered very unlikely that a local resident would be located at the site boundary for 100% of the time, and instead a scenario based on a regular walker who spends two hours per week at the site boundary has been used.

The annual integrated TLD dose for each operational BWR (over 8760 hours) was weighted at an occupancy of 104 hours per year, and the average taken of the resulting dose rates. This is an average based on the maximum reported annual dose values for each site and hence can be considered a cautious value. Following this approach, the annual radiation dose due to direct radiation for the Stage 1 and Stage 2 BWRX-300 dose assessment is estimated to be 8.6  $\mu\text{Sv/y}$ , recognizing that there is a large uncertainty associated with this value at this stage.

The direct radiation assessment will become more refined as the project progresses.

### 9.3.4 Stage 1 Assessment Methodology

#### 9.3.4.1 Stage 1 Liquid Discharge

For releases to an estuary or coastal water, the exposure group considered is a coastal fishing family who are exposed to the radioactive discharge via:

- External radiation from radionuclides deposited in shore sediments
- Consumption of seafood incorporating radionuclides

Dose to marine reference organisms inhabiting the coastal environment is also considered.

The DPUR values in IRAT2 have been calculated for a release into a local marine compartment with a volumetric exchange rate of 100  $\text{m}^3/\text{s}$ . Assumptions include:

- Radionuclides with a half-life less than three hours are not considered
- All shellfish and 50% of fish are assumed to be from the local compartment
- Coastal wildlife is assumed to dwell in the sea immediately offshore from the point of release

DPUR values are presented in Table 4 of the Initial Radiological Assessment Tool 2: Part 1 User Guide (Reference 9-1) for a fishing family coastal release scenario.

The Stage 1 dose to the representative person is calculated as the BWRX-300 SMR annual average liquid release rate multiplied by the relevant DPUR value, scaled by the default IRAT2 average coastal exchange rate of 30  $\text{m}^3/\text{s}$  to provide a conservative dilution.

## NEDO-34226 Revision C

It is noted that the BWRX-300 has been designed such that it can be operated under normal conditions with a maximum recirculation philosophy. However, as it cannot be guaranteed that a liquid discharge will never be made, three scenarios have been modelled for the purpose of the prospective dose assessment:

- Scenario 1: No liquid discharge
- Scenario 2: Maximum liquid discharge volume of 5,968 m<sup>3</sup>/y
- Scenario 3: Liquid discharge volume of 600 m<sup>3</sup>/y. This is comparable to that used for the UK ABWR (560 m<sup>3</sup>/y at the outlet of the High Chemical Impurity Waste System, GA919901-0025-00001, "UKABWR Generic Design Assessment Quantification of Discharges and Limits," (Reference 9-34) and is about 10% of the maximum volume of liquid discharge (scaling factor of 0.101 used) in BWRX-300 Annual Average Liquid Effluent Activity Releases (Reference 9-6)).

In the case of Scenario 3, this would effectively constitute a short-term discharge. However, NDAWG guidance, "Guidance on short term release assessments," (Reference 9-35) considers that the total dose assessed for the 12 monthly limits released in short releases will not differ significantly from the dose assessed assuming a continuous release.

If there is no liquid discharge, tritium releases are assumed to be included in the gaseous discharge. In the event that there is a liquid discharge, then an assumption is made as to the tritium component. For the prospective dose assessment, it has been assumed that the concentration of tritium is the same as in the reactor coolant (water phase), 005N4258, "BWRX-300 Coolant Radiation Concentrations," (Reference 9-36) which would be equivalent to an activity of 3.10E+12 Bq/y for a maximum discharge volume of 5,968 m<sup>3</sup>/y (Scenario 2) or 3.12E+11 Bq/y (Scenario 3).

Despite IRAT2 providing DPUR values for over 100 radionuclides, there are 23 radionuclides<sup>1</sup> in the BWRX-300 liquid discharge source term that are not listed in IRAT2 and so do not have a DPUR. In this instance, the IRAT2 methodology directs the use of the default 'other alpha' and 'other beta/gamma' categories. It is noted that the other beta/gamma category is modelled as Cs-137. For the Stage 1 assessment, the other beta/gamma activity is the sum of the activities of radionuclides without a DPUR as below:

- Scenario 1 – no liquid discharge
- Scenario 2 – 5.81E+08 Bq/y
- Scenario 3 – 5.84E+07 Bq/y

### 9.3.4.2 Stage 1 Gaseous Discharge

For releases to air, the human exposure group considered is a local resident family who are exposed to the radioactive discharge via:

- Inhalation of radionuclides in the effluent plume
- External radiation from radionuclides in the effluent plume and deposited to the ground
- Consumption of terrestrial food incorporating radionuclides deposited to the ground

Terrestrial wildlife reference organisms inhabiting areas exposed to the effluent plume and deposition on the ground are also considered.

---

<sup>1</sup> For a liquid discharge, the following radionuclides do not have a DPUR in IRAT2 and have been modelled as 'other beta/gamma': Ba-139, Br-83, Ce-143, I-132, La-142, Mn-56, Nb-98, Nd-147, Ni-65, Np-239, Pr-143, Ru-105, Sr-91, Sr-92, Te-129m, Te-131m, Te-132, W-187, Y-91, Y-92, Y-93, Zn-69m, Zr-97



## NEDO-34226 Revision C

The DPUR values in the IRAT2 tool have been determined for a release at ground level under 50% category D conditions (neutral stability, typically overcast). The local resident and terrestrial wildlife are located at 100 m from the release point for 100% of the time, food is produced at 500 m from the release point, and radionuclides with a half-life of less than three hours are not being considered for consumption of food as the radionuclides will have decayed prior to consumption. DPUR values are presented in Table 2 of the Initial Radiological Assessment Tool 2: Part 2 Methods and Input Data (Reference 9-2) for a local resident family atmospheric release scenario.

The Stage 1 dose to the representative person is calculated as the BWRX-300 SMR annual average gaseous release rate multiplied by the relevant DPUR value. The discharge is made at ground level.

IRAT2 provides DPUR values for over 100 radionuclides, but there are 26 radionuclides<sup>2</sup> in the BWRX-300 gaseous annual average discharge source term that are not listed in IRAT2 and so do not have a DPUR. In this instance, the IRAT2 methodology directs the use of the default 'other alpha' and 'other beta/gamma' categories. It is noted that the 'other beta/gamma' category is modelled as Cs-137.

However, for noble gases<sup>3</sup> it is considered that the use of the default radionuclide DPUR values are not appropriate as this will lead to overestimation of inhalation and ingestion doses which are not viable exposure pathways for noble gases. Two approaches to modelling the impact of noble gases that do not have a DPUR have been taken and compared, which are:

- Modelling noble gases as Xe-133<sup>4</sup>.
- Modelling noble gases as Kr-88 using a derived DPUR<sup>5</sup> of  $5.10\text{E-}12$   $\mu\text{Sv/y}$  per Bq/y (more cautious approach, noting that the DPUR for Kr-88 is a factor of 70 higher than the DPUR for Xe-133).

When assessing the dose due to gaseous discharges, no reduction has been made to the tritium component to account for liquid discharge Scenarios 2 or 3, effectively double accounting for the tritium in the bounding case.

### 9.3.5 Stage 2 Assessment Methodology

#### 9.3.5.1 Stage 2 Liquid Discharge

The Stage 2 assessment for liquid discharges refines the Stage 1 assessment by selecting a more representative (less conservative) coastal exchange rate.

Although there is not yet a selected site location for the BWRX-300, PER Chapter E2 (Reference 9-3) Table 9.4 identifies a number of sites potentially suitable for the deployment of new nuclear power stations in England and Wales before the end of 2025. These are listed in Table 9-4 along with the IRAT2 coastal exchange rate for each location. A higher coastal exchange rate will reduce the calculated dose due to increased dispersion. For the Stage 2

---

<sup>2</sup> For a gaseous discharge, the following radionuclides do not have a DPUR in IRAT2 and have been modelled as 'other beta/gamma': Cs-138, Np-239, Pr-144, Rb-89, Rh-103m, Rh-106, Sb-124, Sr-91, Sr-92, Te-129m, Te-131m, Te-132, W-187, Y-91, Y-92, Y-93

<sup>3</sup> For a gaseous discharge, the following radionuclides do not have a DPUR in IRAT2 and have been modelled separately as both Xe-133 and as Kr-88: Kr-83m, Kr-87, Kr-88, Kr-89, Xe-131m, Xe-133m, Xe-135, Xe-135m, Xe-137, Xe-138

<sup>4</sup> This is the approach taken in the Rolls Royce Step 1 and Step 2 prospective radiological assessment, SMR0004490, "E3S Case Chapter 30: Prospective radiological assessment," (Reference 9-37)

<sup>5</sup> This is the approach taken in the UK HPR1000 GDA, HPR/GDA/PCER/0007, "Pre-Construction Environmental Report Chapter 07 Radiological Assessment," (Reference 9-38)

## NEDO-34226 Revision C

dose assessment, a coastal exchange rate of 231 m<sup>3</sup>/s has been selected as a suitably conservative value.

Another key refinement for the Stage 2 assessment is to review how realistic any use of the default 'other alpha' and 'other beta/gamma' categories has been. These can be substituted with specific radionuclides if the typical composition of the discharge is known. Table 16 of IRAT2 (Reference 9-1) provides guidance as to the suggested radionuclides which result in the highest doses in each category.

Considering the 23 radionuclides in the BWRX-300 liquid discharge source term which do not have a DPUR, it can be seen in Table 9-5 that the majority are fission products, for which Cs-137 would remain the most appropriate surrogate radionuclide. For those few radionuclides that are not fission products, the IRAT2 guidance (Reference 9-1) has been followed, noting that both Mn-52 and Pb-212 have a slightly lower total DPUR than Cs-137.

For the Stage 2 assessment, the radionuclides in Table 9-5 will be modelled in IRAT2 as per the categories shown in Table 9-6, where the Bq/y activities presented are the sum of the activities of the individual radionuclides being modelled in each category.

It is noted that the 'other beta/gamma' category used in the Stage 1 assessment is also modelled as Cs-137. For the human dose assessment, the DPURs for Pb-212 and Mn-54 are smaller than the DPUR for Cs-137. However, for the wildlife dose assessment, Pb-212 has a significantly higher dose rate per unit release than Cs-137 and so results in a much more cautious dose to wildlife.

### 9.3.5.2 Stage 2 Gaseous Discharge

The Stage 1 dose to the representative person was calculated for a gaseous discharge at ground level. For the Stage 2 refined assessment, an effective release height of 11.7 m has been used based on application of the one-third reduction rule, NRPB-R157 "The Fifth Report of a Working Group on Atmospheric Dispersion, Models to Allow for the Effects of Coastal Sites, Plume Rise and Buildings on Dispersion of Radionuclides and Guidance on the Value of Deposition Velocity and Washout Coefficients," (Reference 9-39) to a stack height of 35 m, 005N9751, "BWRX-300 General Description," (Reference 9-40). The higher discharge elevation results in increased dispersion, which in turn reduces the radiation dose received from food and (more significantly) from inhalation and external exposure.

As for the Stage 2 liquid discharge assessment, a review was performed of the radionuclides modelled as 'other beta/gamma' during the Stage 1 assessment.

Considering the 26 radionuclides in the BWRX-300 gaseous discharge source term which do not have a DPUR, it can be seen in Table 9-7 that, again, the majority are fission products, for which Cs-137 would remain the most appropriate surrogate radionuclide. For those few radionuclides that are not fission products, the IRAT2 (Reference 9-1) guidance has been followed, noting that both Mn-52 and Pb-210 have a slightly lower total DPUR than Cs-137.

For the Stage 2 assessment, the radionuclides in Table 9-7 will be modelled in IRAT2 as per the categories shown in Table 9-8.

It is noted that the 'other beta/gamma' category used in the Stage 1 assessment is also modelled as Cs-137. For both the human dose assessment and the wildlife dose assessment, Cs-137 provides a more cautious dose estimate than the Mn-52 and Pb-212 surrogates.

NEDO-34226 Revision C

## **9.4 Dose Assessment Results and Discussion**

### **9.4.1 Stage 1 Assessment**

#### **9.4.1.1 Stage 1 Dose to the Representative Person – Liquid Discharge**

Table 9-9 presents the IRAT2 Stage 1 estimated doses to the representative person for each liquid discharge scenario. Table 9-10 and Table 9-11 present a breakdown of the dose by radionuclide and pathway for those radionuclides contributing more than 1% to the total dose, plus tritium.

The full IRAT2 Stage 1 dose to the representative person for the Scenario 2 bounding case is provided in Appendix A Table A-1 and the Stage 1 dose to wildlife in Appendix A Table A-2.

#### **9.4.1.2 Stage 1 Dose to the Representative Person – Gaseous Discharge**

Table 9-12 presents the IRAT2 Stage 1 estimated doses to the representative person when the noble gases are modelled as Xe-133 and as Kr-88. Table 9-13 and Table 9-14 present a breakdown of the dose by radionuclide and pathway for those radionuclides contributing more than 1% to the total dose.

The full IRAT2 Stage 1 dose to the representative person with Xe-133 as surrogate is provided in Appendix A Table A-3, equivalent calculations with Kr-88 as surrogate in Appendix A Table A-4, and the Stage 1 dose to wildlife in Appendix A Table A-5.

#### **9.4.1.3 Stage 1 Dose to the Representative Person and Wildlife – Discussion**

For liquid discharges, the total dose to the worst affected member of the fishing family was estimated to be 5.5  $\mu\text{Sv/y}$  for the bounding Scenario 2 case.

The dose due to the liquid discharge was dominated by Co-60 (54.0%), Zn-65 (17.0%), and P-32 (12.2%).

The dose rate to the worst affected organism (polychaete worm) was 3.1E-02  $\mu\text{Gy/h}$  and was dominated by Co-60 (33.7%), Ba-140 (27.6%), and Mn-54 (10.9%).

For gaseous discharges, the total dose to the worst affected member of the local resident family depended upon how the noble gases were modelled. Using Xe-133 as a surrogate resulted in a dose of 34.0  $\mu\text{Sv/y}$  which was dominated by C-14 (83.2%), I-131 (6.9%), and Xe-133 (4.4%). Using Kr-88 as the surrogate resulted in a much higher dose of 128  $\mu\text{Sv/y}$  due to the external irradiation DPUR for Kr-88 being much higher than the DPUR for Xe-133 (5.0E-12 compared to 7.12E-14  $\mu\text{Sv/y per Bq/y}$ ), which was dominated by Kr-88 (74.9%, with Kr-89 dominating this at 46.8%), C-14 (21.8%), and I-131 (1.8%).

With Xe-133 as a surrogate, the dose rate to the worst affected organism (bird, large mammal, small-burrowing mammal, reptile) was 5.0E-02  $\mu\text{Gy/h}$  and was dominated by C-14 (90.1%). A dose rate was not calculated with Kr-88 as a surrogate as this radionuclide is not available within the IRAT2 tool.

The IRAT2 stage 1 dose assessment for liquid and gaseous discharges plus direct radiation dose is summarized in Table 9-15. The total dose is estimated to be 48.1  $\mu\text{Sv/y}$  if noble gases are modelled as Xe-133 and 142.3  $\mu\text{Sv/y}$  if noble gases are modelled as Kr-88, reflecting the much higher DPUR value for Kr-88 compared to Xe-133. Both total dose values exceed the 20  $\mu\text{Sv/y}$  threshold and are dominated by the gaseous discharge.

### **9.4.2 Stage 2 Assessment**

#### **9.4.2.1 Stage 2 Dose to the Representative Person – Liquid Discharge**

Table 9-16 presents the IRAT2 Stage 2 estimated doses to the representative person for each liquid discharge scenario. Table 9-17 and Table 9-18 present a breakdown of the dose by radionuclide and pathway for those radionuclides contributing more than 1% to the total dose,

## NEDO-34226 Revision C

plus tritium. The reduction in the Stage 2 marine doses compared to the Stage 1 marine doses are a consequence of the increased dispersion of the liquid discharge due to the higher coastal exchange rate.

The full IRAT2 Stage 2 dose to the representative person for the Scenario 2 bounding case is provided in Appendix A Table A-6 and the Stage 2 dose to wildlife in Appendix A Table A-7.

### 9.4.2.2 Stage 2 Dose to the Representative Person – Gaseous Discharge

Table 9-19 presents the IRAT2 Stage 2 estimated doses to the representative person when the noble gases are modelled as Xe-133 and as Kr-88. Table 9-20 and Table 9-21 present a breakdown of the dose by radionuclide and pathway for those radionuclides contributing more than 1% to the total dose. The reduction in the Stage 2 terrestrial doses compared to the Stage 1 terrestrial doses are a consequence of the increased dispersion of the gaseous discharge due to the much higher release height.

The full IRAT2 Stage 2 dose to the representative person with Xe-133 as surrogate is provided in Appendix A Table A-8, equivalent calculations with Kr-88 as surrogate in Appendix A Table A-9, and the Stage 2 dose to wildlife in Appendix A Table A-10.

### 9.4.2.3 Stage 2 Dose to the Representative Person and Wildlife – Summary and Discussion

For liquid discharges, the total dose to the worst affected member of the fishing family was estimated to be 0.71  $\mu\text{Sv/y}$  for the bounding Scenario 2 case.

The dose due to the liquid discharge was dominated by Co-60 (54.8%), Zn-65 (17.3%), and P-32 (12.4%).

The dose rate to the worst affected organism (phytoplankton) was  $4.7\text{E-}02 \mu\text{Gy/h}$  and was dominated by Pb-212 (90.7%), however this is a feature of the high dose rate per unit release value for Pb-212. For comparison, if all of the radionuclides without a DPUR had been modelled as Cs-137 (i.e., only the coastal exchange rate had been changed between Stage 1 and Stage 2) then the dose rate to the worst affected organism would have been  $1.4\text{E-}03 \mu\text{Gy/h}$  (polychaete worm) and be dominated by Co-60 (33.7%). However, even with the more cautious approach of using Pb-212 as the surrogate, the dose to wildlife is well below the statutory dose rate threshold of  $40 \mu\text{Gy/h}$  and the EA screening threshold of  $1 \mu\text{Gy/h}$ .

For gaseous discharges, the total dose to the worst affected member of the local resident family depended upon how the noble gases were modelled. Using Xe-133 as a surrogate resulted in a dose of  $11.2 \mu\text{Sv/y}$  which was dominated by C-14 (84.0%) and I-131 (11.9%). Using Kr-88 as the surrogate resulted in a slightly higher dose of  $18.2 \mu\text{Sv/y}$  which was dominated by C-14 (53.1%), Kr-88 (36.9%, with Kr-89 dominating at 23.1%), and I-131 (7.5%).

With Xe-133 as a surrogate, the dose rate to the worst affected organism (bird, large mammal, small-burrowing mammal, reptile) was  $3.2\text{E-}02 \mu\text{Gy/h}$  and was dominated by C-14 (90.1%). A dose rate was not calculated with Kr-88 as a surrogate as this radionuclide is not available within the IRAT2 tool.

The IRAT2 Stage 2 dose assessment for liquid and gaseous discharges plus direct radiation dose is summarised in Table 9-22, using the bounding Scenario 2 case for the liquid discharge. The total dose is estimated to be  $20.5 \mu\text{Sv/y}$  if noble gases are modelled as Xe-133 and  $27.5 \mu\text{Sv/y}$  if noble gases are modelled as Kr-88, with the increased dispersion due to the increase in release height resulting in more comparable doses, even where Kr-88 is the surrogate. Both total dose values are slightly above the  $20 \mu\text{Sv/y}$  threshold and are dominated by the contribution from the gaseous discharge.

## NEDO-34226 Revision C

### 9.4.3 Conclusion

Results for the Stage 1 dose assessment estimated a worst-case total dose of 142  $\mu\text{Sv/y}$  to the representative person for members of the public for liquid and gaseous discharges and direct radiation. This dose is:

- Well below the single site dose constraint of 500  $\mu\text{Sv/y}$  (Reference 9-8, Reference 9-25)
- Below the source constraint of 300  $\mu\text{Sv/y}$  (Reference 9-8, Reference 9-25)
- Just below the advisory lower dose constraint of 150  $\mu\text{Sv/y}$ , RCE-12 (Reference 9-17)
- Greater than the Stage 1 screening threshold of 20  $\mu\text{Sv/y}$  (Reference 9-1, Reference 9-19)

For NHS, the Stage 1 estimated dose rate to the worst affected organism was well below the statutory dose rate threshold level of 40  $\mu\text{Gy/h}$  and the EA screening level of 1  $\mu\text{Gy/h}$  (Reference 9-1, Reference 9-19) for both liquid and gaseous discharges.

Results for the Stage 2 dose assessment estimated a worst-case total dose of 27.5  $\mu\text{Sv/y}$  to the representative person for members of the public for liquid and gaseous discharges and direct radiation. This dose is:

- Well below the single site dose constraint of 500  $\mu\text{Sv/y}$  (Reference 9-8, Reference 9-25)
- Well below the source constraint of 300  $\mu\text{Sv/y}$  (Reference 9-8, Reference 9-25)
- Well below the advisory lower dose constraint of 150  $\mu\text{Sv/y}$ , RCE-12 (Reference 9-17)
- Slightly above the Stage 2 screening threshold of 20  $\mu\text{Sv/y}$  (Reference 9-1, Reference 9-19)

For NHS, the Stage 2 estimated dose rate to the worst affected organism was well below the statutory dose rate threshold level of 40  $\mu\text{Gy/h}$  and the EA screening level of 1  $\mu\text{Gy/h}$  (Reference 9-1, Reference 9-25) for both liquid and gaseous discharges.

The Stage 2 dose assessment is slightly above the IRAT2 20  $\mu\text{Sv/y}$  screening limit (Reference 9-1), but this will be refined in a more realistic detailed radiological impact assessment in support of environmental permitting applications.

These results demonstrate that, even for the conservative bounding scenarios, at a fundamental level the design is capable of meeting UK dose constraints, noting that the future owner/operator is not committed to the chosen modelled scenarios.



NEDO-34226 Revision C

## **9.5 Proposed Methodology for Stage 3 Assessment of Radiation Doses due to Continuous Liquid and Gaseous Discharge**

### **9.5.1 Introduction**

GEH has entered into the GDA process up to Step 2. The refined radiological assessment (Stage 3) which would ordinarily be undertaken in GDA Step 3 is still required to support environmental permitting applications for the BWRX-300. An outline of the proposed methodology is provided below.

Step 3 of the GDA process for the BWRX-300 requires a more realistic assessment of the radiological impacts of routine liquid and gaseous discharges to the environment. The steps for this more realistic assessment are as summarised below (Reference 9-19).

- Identify/quantify the source term
- Model radionuclide transfer in the environment
- Determine exposure pathways
- Identify habits and data for the exposure pathways
- Determine the candidates for the representative person from a realistic combination of habits
- Estimate doses to the candidates for the representative person
- Determine the representative person
- Calculate the total dose (including historical and future discharges and direct radiation)

The following sections outline the proposed approach for performing the more realistic detailed assessment, along with an outline approach for the assessment of collective dose, dose due to build-up of radionuclides in the environment, and the dose associated with a short-term release.

The proposed methodology references use of both generic and site-specific data noting that, if available, site-specific data should always be used in preference to generic data for the refined dose assessment.

### **9.5.2 BWRX-300 Source Term**

The Stage 1 and Stage 2 dose assessment was performed using the annual average liquid and gaseous discharge source terms, which included AOOs. These source terms are recognised to be very conservative, as discussed in PER Chapter E7 (Reference 9-7) Section 7.2.4.3, and it was considered that current inclusion of additional headroom factors would have added in further conservatism and resulted in an overly pessimistic dose assessment.

However, the BWRX-300 source term will be developed and refined as the GDA process progresses, with forward actions raised across the project (FAP.PSR23-133 and FAP.PER7-196). GEH expect the gaseous and liquid discharge activities to reduce once refined End User Source Terms (EUST) and the liquid discharge volume are confirmed. Source term work will look at AOOs, reviewing the EUST against 2004/2 Euratom recommendations, consideration of sources of liquid or gaseous radioactive discharge introduced from outside of the nuclear island, headroom factors, and the proposed discharge limits.

The Stage 3 dose assessment will be performed using the BWRX-300 refined source term.

## NEDO-34226 Revision C

### 9.5.3 Dose Assessment Modelling

The Environment Agencies make no specific recommendation as to the specific environmental dispersion and dose assessment model to be used for the detailed assessment (Reference 9-19) but note that the PC-CREAM (Consequences of Releases to the Environment Assessment Methodology) Radiological Impact Assessment Software, HPA - RPD-058, "The Methodology for Assessing the Radiological Consequences of Routine Releases of Radionuclides to the Environment Used in PC-CREAM 08," (Reference 9-41) is a suitable model for many applications. It is proposed that PC-CREAM 08 is used for the Stage 3 BWRX-300 dose assessment.

PC-CREAM 08 comprises a suite of models and databases which can be used to perform prospective radiological impact assessment of both individual and collective doses for routine, continuous liquid and gaseous discharges.

PC-CREAM 08 includes a dose assessment program called ASSESSOR which uses mathematical models to predict the transfer of radionuclides through the environment (which includes the food chain) and provide estimates of activity concentrations in various environmental media (for example, sea water, seabed sediment and soil) following a continuous release. PLUME, RESUS, GRANIS, and FARMLAND consider dispersion following a gaseous release, and DORIS looks at marine dispersion.

The PC-CREAM 08 models have been verified and validated, UKHSA-RCE-004, "Verification and validation of models used in radiological assessment tools PACE and PC-CREAM 08," (Reference 9-42) and are widely used within the nuclear industry for dose assessment modelling.

### 9.5.4 Dispersion Modelling

#### 9.5.4.1 Modelling of Liquid Discharges to the Marine Environment

A more detailed description of DORIS can be found in the UKHSA verification report for PC-CREAM 08, UKHSA-RCE-004 (Reference 9-42).

The PC-CREAM 08 DORIS module estimates activity concentrations in sea water, marine sediments, and marine biota.

DORIS allows specification of the site location; radionuclides and discharge rates; element dependent parameters (sediment distribution coefficients and concentration ratios for marine biota); local marine compartment characteristics; regional compartment characteristics; volumetric exchange rates; output materials (filtered and unfiltered seawater, suspended solids, seabed sediments, fish, crustaceans, seaweed, and molluscs); and the output time(s) in years.

As highlighted in Section 9.3.4.1, the BWRX-300 has been designed such that it can be operated under normal conditions with a maximum recirculation philosophy which minimises the liquid discharge to the environment. This mode of operation is supported by a review, NEDC-34279P, "BWRX-300 UK GDA Analysis of Environmental Discharge Data for U.S. Nuclear Power Plants," (Reference 9-43) of publicly available data for U.S. NPPs which showed that several U.S. BWR plants operate on a zero liquid discharge basis and have done so for many years. Other U.S. BWRs generally operate on a zero liquid discharge basis with occasional liquid discharges. It will be for the BWRX-300 plant owner / operator to determine the operational requirements for liquid discharges at the site-specific stage.

An occasional liquid discharge would effectively constitute a short-term discharge to the environment, something which PC-CREAM 08 is not suitable to assess. NDAWG explicitly considers and provides guidance regarding a short-term discharge to coast/estuary (Reference 9-35). NDAWG concludes that as there is little annual variation in dispersion (which is largely driven by tidal currents) or in habits (fish consumption and occupancy on

## NEDO-34226 Revision C

sediments), and fish are a mobile population within coastal and estuarine waters (so unlikely to be constantly exposed to a short-term plume) the total dose assessed for the 12 monthly limits released in short releases will not differ significantly from the dose assessed assuming a continuous release. For this reason, NDAWG conclude that there is unlikely to be a need for a short-term release assessment for discharges of radioactive substances to estuaries or coastal environments.

It is considered that for Stage 3, the DORIS module in PC-CREAM 08 is a suitable software tool to assess the radiological impact of a liquid discharge from the BWRX-300 which will be modelled as a continuous release. Data reflecting the generic site would be used for the Stage 3 refined assessment, and data for the specific site for the detailed assessment.

### 9.5.4.2 Modelling of Gaseous Discharges to the Terrestrial Environment

PC-CREAM 08 uses the PLUME module which calculates activity concentrations in air, deposition rates, and external gamma dose rates from radionuclides in the cloud (cloud gamma) at various distances downwind of the release point. The GRANIS module estimates the external exposure to gamma radiation from radionuclides deposited on the ground. The FARMLAND module predicts the transfer of radionuclides into terrestrial foods following deposition onto the ground. The RESUS module estimates the activity concentrations in air arising from the resuspension of previously deposited radionuclides. Each of these four modules is discussed in more detail below.

PC-CREAM 08 is not suitable for assessment of radiological impacts due to short-term gaseous discharges to the environment, which must be considered separately via a different methodology, as discussed in Section 9.5.11.

#### PLUME

A more detailed description of PLUME can be found in the UKHSA verification report for PC-CREAM 08, UKHSA-RCE-004 (Reference 9-42).

PLUME is based on a Gaussian plume model, HPA-RPD-058 (Reference 9-41) and considers the meteorological conditions during the release, the roughness of the land surface and the physical characteristics of the radionuclides being released to calculate the atmospheric dispersion at specified distances downwind of the release point.

The latest available BWRX-300 refined source term will be used to specify the radionuclides and discharges rates, alongside user defined distances that will represent the locations of interest (e.g., location of food production, location of habitations).

The effective release height used for the Stage 2 dose assessment was 11.7 m based on a stack height of 35 m. An effective release height will again be required at Stage 3 to account for entrainment of the plume by nearby buildings as PC-CREAM 08 does not account for this effect and could otherwise potentially underestimate concentrations close to the release point. As at Step 2, an effective stack height will be defined using the one-third reduction rule (Reference 9-39) which will again result in a proposed effective discharge height of 11.7 m for a refined Stage 3 assessment based on a generic site. For the Stage 3 site-specific dose assessment, a stack height study based on dispersion modelling is recommended to determine the optimum stack height above which the benefits of increasing height will have limited impact on further reducing ground level activity concentrations.

A surface roughness of 0.3 m is proposed for near-field modelling, which is typical for agricultural areas, and the lowest PC-CREAM 08 surface roughness option of 0.01 m is proposed for long-range dispersion modelling which is typical of the sea or very short grass.

PC-CREAM 08 offers three meteorological sampling schemes (Doury, Hosker-Smith or Pasquill), each with six stability categories ranging from A (most turbulent) to F (most stable).



## NEDO-34226 Revision C

It is proposed to use the default PC-CREAM 08 scheme (Hosker-Smith) for the Stage 3 detailed dose assessment.

For the Stage 3 site-specific dose assessment, it is proposed that a site-specific meteorological data file would be generated based upon data for the proposed site for a defined time period (e.g. 10 years) which can be requested from the UK Meteorological Office. This data can be converted into a meteorological data input file that can be used by PC-CREAM 08. The site-specific meteorological data will more accurately predict gaseous dispersion and deposition rates based on the typically prevailing wind direction and can be used to identify the most appropriate geographical locations for both residential occupancy and food production for input to the site-specific dose assessment.

### GRANIS

A more detailed description of GRANIS can be found in UKHSA-RCE-004 (Reference 9-42).

GRANIS estimates both the activity concentration of radionuclides in the soil and the corresponding external ground gamma dose, considering the shielding properties of the soil when estimating doses 1 m above the soil surface.

The latest available BWRX-300 refined source term will be used to specify the radionuclides and a deposition rate of 1 Bq/m<sup>2</sup>/s is proposed for the assessment to allow scaling.

GRANIS offers two soil models, undisturbed and well mixed, each having a depth profile that can be defined as generic wet or generic dry soil. It is proposed that the Stage 3 dose assessment uses the undisturbed soil model with a generic wet soil profile, which is broadly representative of the conditions expected for a generic coastal site.

### FARMLAND

A more detailed description of FARMLAND can be found in UKHSA-RCE-004 (Reference 9-42).

FARMLAND comprises a suite of models (cows, sheep, fruit, grain, green vegetables, and root vegetables) that can be used to predict the transfer of radionuclides into terrestrial foods following deposition onto the ground. It is not proposed to include grain in the Stage 3 assessment as grain is usually farmed, processed, and consumed at a national rather than local level, nor is it proposed to include food products from poultry and pigs, as these are often reared indoors and fed from nationally produced foodstuffs.

The latest available BWRX-300 refined source term will be used to specify the radionuclides and a deposition rate of 1 Bq/m<sup>2</sup>/s is proposed for the Stage 3 assessment to allow scaling. PC-CREAM 08 defaults are proposed to be used for plant and animal dependent model parameters, concentration ratios, animal equilibrium transfer factors, and other element dependent parameters.

### RESUS

More information on RESUS can be found in HPA-RPD-058 (Reference 9-41) and UKHSA - RCE-004 (Reference 9-42).

Resuspension can occur due to either man-made or wind-initiated disturbance. RESUS models, wind-driven resuspension, and estimates activity concentrations in air arising from the resuspension of previously deposited radionuclides using a formula which is independent of the radionuclide considered aside from accounting for radioactive decay. A time-dependent resuspension factor is used to reflect that material becomes less available for resuspension over time.

## NEDO-34226 Revision C

### 9.5.5 Exposure Pathways

The following exposure pathways to people from the activity concentrations and dose-rates in environmental media are proposed.

#### 9.5.5.1 Pathways for Marine Discharges

The marine pathways considered to be relevant for the Stage 3 generic site dose assessment are:

- Ingestion: internal exposure from ingestion of locally caught seafood (fish, crustaceans, mollusks, seaweed).
- Inhalation: internal exposure from inhalation of sea-spray.
- External irradiation: external exposure from beta/gamma radionuclides in beach sediment and from handling contaminated fishing equipment.

The above proposed marine pathways are considered appropriate for a generic site dose assessment but must be reviewed against local habit data before confirming that they are appropriate for the site-specific dose assessment. At the site-specific assessment stage alternative or additional marine exposure pathways may be identified.

#### 9.5.5.2 Pathways for Gaseous Discharges

The terrestrial pathways considered to be relevant for the Stage 3 generic site dose assessment are:

- Ingestion: internal exposure from ingestion of locally produced foodstuffs.
- Inhalation: internal exposure from inhalation of radionuclides in the gaseous plume and of deposited radionuclides that have been resuspended.
- External irradiation: external exposure from radionuclides in the gaseous plume and from deposited radionuclides.
- Skin absorption of tritium.

The above proposed gaseous pathways are considered appropriate for a generic site dose assessment but must be reviewed against local habit data before confirming that they are appropriate for the site-specific dose assessment. At the site-specific assessment stage alternative or additional gaseous exposure pathways may be identified.

#### 9.5.5.3 Other Pathways

The following additional pathway is proposed:

- Direct radiation

Exposure of members of the public at the site boundary to external radiation associated with BWRX-300 facilities. The assumption for the Stage 1 and Stage 2 assessment was 8.6  $\mu\text{Sv/y}$  based on Operating Experience (OPEX) from U.S. BWRs, however this nominal value was recognised to have a large uncertainty. It is proposed that the direct dose be refined based on mathematical modelling of key buildings (e.g. turbine hall, reactor building, waste storage facilities) using an industry standard shielding code. Models would be produced of key facilities containing the relevant source term, and dose rates calculated at defined receptor points. For a generic site, this could be at defined distances from each facility (100 m, 500 m), and at the site-specific stage this would be at receptor locations corresponding to key points along the site perimeter, the local resident's location, local settlements and any other key terrestrial receptors identified.

A review of public occupancy rates would also be performed for the reference age groups (infant, child, adult), either using generalised habit data for the generic site or radiological

## NEDO-34226 Revision C

habits survey data for a site-specific assessment. These occupancies would be used in conjunction with the modeled dose rates to provide a better estimate of the direct radiation dose.

For the site-specific assessment, shielding effects of other buildings, respective heights of buildings and different ground levels could also be considered as part of the modelling. However, shielding from any proposed earth works around the nuclear site would not typically be included, to produce conservative dose rates.

The above proposed direct dose pathway is considered appropriate for a generic site dose assessment but must be reviewed against local habit data before confirming that it is appropriate for the site-specific dose assessment. At the site-specific assessment stage alternative or additional direct dose exposure pathways may be identified.

The BWRX-300 design reduces direct dose through the implementation of a comprehensive As Low As Reasonably Achievable (ALARA) programme, as described in BWRX-300 ALARA Design Criteria for Standard Design (Reference 9-21).

It is anticipated that the following pathways will be excluded from both the Stage 3 generic and site-specific dose assessment, however this will be confirmed for the site-specific assessment following a review of local habit data:

- Inadvertent ingestion of seawater and beach sediment, both considered to be minor exposure pathways.
- Consumption of honey, as the point of origin is likely to be outside of that impacted by the gaseous plume, and consumption rates of this foodstuff are comparatively low.
- Consumption of wild game, as the point of origin is likely to be outside of that impacted by the gaseous plume, and consumption rates of this foodstuff are comparatively low.

### 9.5.6 Habit Data

The radiation doses received by the public due to the operation of the BWRX-300 SMR are a combination of radionuclides and activities discharges, the exposure pathways, and individual habits (occupancy at key locations and for key activities and consumption rates of locally produced foodstuffs).

Habit data are available as generic (general use), such as in NRPB-W41, "Generalised habit data for radiological assessments," (Reference 9-44), or site-specific, such as that collected in site-specific radiological habit surveys published by the Centre for Environment, Fisheries and Aquaculture Science (CEFAS), "CEFAS radiological habits survey data," (Reference 9-45).

It is proposed that the Stage 3 detailed dose assessment will be based on generic habits data as presented in NRPB-W41 (Reference 9-44) and that the Stage 3 site-specific dose assessment will use habit data taken from the relevant CEFAS radiological habits survey report (Reference 9-45) for the identified exposure pathways.

NDAWG provides guidance on the use of habits data for prospective dose assessments, "Use of Habits Data in Prospective Dose Assessments," (Reference 9-46) and recommends use of the 'top two' method using generic UK habit data when site-specific data is unavailable. This approach is judged by NDAWG to result in a reasonably realistic assessment of doses for the next 5-10 years, which will be more conservative and give higher doses than using habits profiles. A top two assessment is made with all terrestrial food intakes initially set to critical levels to identify the two terrestrial food types that give rise to the highest doses. These two foods are then retained with a critical intake and the remaining foods are ingested at 50th percentile levels.

## NEDO-34226 Revision C

It is proposed that the BWRX-300 Stage 3 detailed generic dose assessment uses the top two approach and generic UK habit data to refine the Stage 2 dose assessment. It will be assumed that all shellfish and 0% of the fish are caught from a local compartment adjacent to the generic site, with the other 50% of the fish assumed to be caught in a larger surrounding region, termed the 'regional compartment' (Reference 9-1). Terrestrial foods will be assumed to be 100% locally sourced, with milk, cow, and sheep meat being produced at a local farm, and vegetables and fruit being grown at the local habitation.

It is proposed that the BWRX-300 Stage 3 site-specific dose assessment uses the top two approach and the CEFAS site-specific habit data to refine the Stage 3 detailed dose assessment. It will be assumed that all shellfish and 50% of the fish are caught from the local compartment adjacent to the proposed site, with the other 50% of the fish assumed to be caught in the 'regional compartment' for the proposed site (Reference 9-1). Terrestrial foods will be assumed to be 100% locally sourced, with milk, cow, and sheep meat being produced at a local farm, and vegetables and fruit being grown at the local habitation.

### 9.5.7 Candidates for the Representative Person

The representative person is defined as the individual receiving a dose that is representative of the more highly exposed individuals in the population, RCE-12 (Reference 9-17). To identify the representative person, an assessment is made looking at different groups of individuals who have different exposure profiles, the Candidates for the Representative Person (CRP). The representative person will be the CRP who has the highest estimated dose.

The CRP should reflect a realistic combination of habits based on local knowledge or plausible assumptions (Reference 9-19). A full range of exposure pathways should be considered for each of the CRP as it is likely that these individuals receive contributions to dose from more than one pathway. It is considered reasonable to assume a combination of average and higher than average habits, for example the CRP for the marine pathway is likely to consume higher than average amounts of seafood but average amounts of terrestrial foods whereas the CRP for the terrestrial pathway is likely to eat higher than average terrestrial foods and average marine foods.

The CRPs proposed for the BWRX-300 SMR are:

1. Liquid discharges: A fishing family (adult, child, and infant) who spend their time on the coast close to the liquid discharge point. The family consume 100% locally caught seafood, inhale sea-spray, are exposed to external radiation due to handling contaminated fishing equipment and are also exposed to contaminated beach sediment. The adults will go fishing near the coast and the child and infant will spend time playing on the beach.
2. Gaseous discharges: A local resident family (adult, child, and infant) living at a dwelling that is close to and downwind of the gaseous discharge, being located at the area of highest deposition rate. The family consume 100% locally produced terrestrial foods, inhale the plume, inhale resuspended material, and are exposed to external radiation both from being immersed in the plume and from deposited activity on the ground. The family are afforded some protection from the plume and from deposited material due to shielding offered by their dwelling but also spend time outdoors.
3. Direct Radiation: Local dog walkers who take the same daily route close to the site perimeter and local residents who live close to the site and access the local beach for recreational activities, which include the fishing family and the local resident family.

The above proposed CRPs are considered appropriate for a generic site dose assessment but must be reviewed against local habit data before confirming that they are appropriate for the site-specific dose assessment. At the site-specific assessment stage alternative or additional CRPs may be identified.

## NEDO-34226 Revision C

The CRP with the highest combined dose from all pathways including direct radiation will be considered the representative person for the BWRX-300 SMR. This total dose will be assessed against the dose limits referenced in Section 9.1.2.2, namely:

- 0.5 millisieverts per year from the discharges from any single site
- 0.3 millisieverts per year from any source
- 0.15 millisieverts per year for new NPPs and new waste disposal facilities (this limit is not yet formal guidance)

### 9.5.8 Individual Dose Assessment for the CRPs

The ASSESSOR module in PC-CREAM 08 will be used to calculate individual doses to adult, child, and infant from gaseous discharges to the atmosphere based on the PLUME, GRANIS, FARMLAND, and RESUS outputs, and individual doses to adult, child, and infant due to liquid discharges based on the DORIS output. ASSESSOR combines the results of the models with actual discharge rates, generic site data, generic habit data, and ICRP60 dose coefficients to calculate effective doses for the identified exposure pathways for different age groups, (UKHSA-RCE-004 (Reference 9-42), "Compendium of Dose Coefficients based on ICRP Publication 60," (Reference 9-47)).

For gaseous releases, the outputs from PLUME, GRANIS, FARMLAND, and RESUS are picked up by ASSESSOR where they are used alongside receptor points and habit data (e.g., ingestion data, occupancy times and inhalation rates) to calculate the individual dose to the CRPs.

For marine discharges, the outputs from DORIS are picked up by ASSESSOR where they are used alongside habit data (ingestion data for adult, child, and infant, occupancy in the local and regional compartment, occupancy and inhalation rate for sea-spray and exposure to fishing equipment) to calculate the individual radiation dose to the CRPs.

Consideration will be made regarding the potential dose to embryo and foetus and to the newborn child, where the dose to the offspring could exceed that of the mother. ICRP have published dose coefficients for assessing these doses, "Doses to the Embryo and Fetus from Intakes of Radionuclides by the Mother," (Reference 9-48) and UKHSA (as HPA) have provided guidance on their applications, RCE-5, "Guidance on the Application of Dose Coefficients for the Embryo, Fetus and Breastfed Infant in Dose Assessments for Members of the Public (RCE-5)," (Reference 9-49), identifying the radionuclides that should be assessed (for example P-32, Ph-33, Ca-45, Sr-89) where they form a significant part of a release to the environment. A review of the updated BWRX-300 source term will be performed to identify if an assessment of the dose to embryo and foetus is required.

The annual effective dose will be calculated assuming that the discharge continues for the expected operating life of the plant (60 years), with the dose assessed for the final year of discharge in accordance with regulatory guidance (Reference 9-19). The total dose due to a combined exposure to both liquid and gaseous discharges and direct radiation (currently assumed to be 8.6  $\mu$ Sv/y but which will be refined at Stage 3) will be estimated by considering:

- The fishing family, who also consume terrestrial foods at average rates and reside at a habitation close to the site where they will be exposed to radionuclides in the plume and deposited by the plume.
- A local resident family, who also consume seafoods at average rates and spend leisure time at the local beach where they will be exposed to radionuclides in the beach sediment and where they will inhale sea spray.



## NEDO-34226 Revision C

The CRP with the highest total dose will be identified as the representative person for the BWRX-300. The estimated doses will be compared to the relevant dose constraints (0.3 mSv and 0.15 mSv).

### 9.5.9 Collective Dose Assessment

The ASSESSOR module in PC-CREAM 08 will be used to perform an assessment of the collective dose to defined population groups (e.g., United Kingdom, EU12, World) using the in-built databases combined with the outputs of the PLUME, GRANIS, FARMLAND, and RESUS models for gaseous discharges and the output of the DORIS model for liquid discharges.

The collective effective dose is the time integrated dose from a single year of discharge, which includes external exposures and the committed effective dose received from intakes of radionuclides. The collective dose assessment considers both "first pass" (the contribution to collective dose that arises as the dispersing plume initially passes over the target population) and "global circulation" components (important for long-lived radionuclides, such as C-14, which are globally dispersed and continue to contribute to the collective dose after long periods of time). The collective dose will be truncated at 500 years.

PC-CREAM 08 divides the area around the discharge point into annular segments, within which the population and agricultural production distributions are assumed to be uniform. The distributions of individual dose and radionuclide concentrations in the environment are also assumed to be uniform. Individual external and inhalation doses in each annular segment of the polar grid are scaled by the population in that segment to calculate the collective dose.

For liquid discharges, collective doses are calculated using the radionuclide concentrations in each compartment and then summing to obtain the total collective dose. Liquid discharge doses to individuals will usually be highest close to the discharge point because of dispersion in the water. Sediment movement between compartments is not considered important within marine environments and as a result is not modelled.

For this assessment, it will be assumed that the population is made up of adults only and that they do not move from one place to another. Default values will be used for the average fraction of time spent indoors and the location factors for exposure to cloud gamma, deposited gamma, cloud beta, deposited beta, and inhalation, where location factors are a measure of the reduction in dose that is likely to arise as a result of being indoors.

The per-caput dose will be calculated from the collective dose for each population group by dividing by the number of individuals in each group.

### 9.5.10 Build-Up Dose Assessment

A build-up of radionuclides in the local environment may impact upon and prejudice the potential future uses (or users of) the land and the sea at the end-of-life of the power station.

The build-up of radionuclides in the terrestrial and marine environment will be calculated at the end of 60 years of continuous operations using PC-CREAM 08.

The DORIS module will be used to determine the activity concentration in filtered and unfiltered seawater (Bq/L) and in seabed sediment (Bq/kg).

The PLUME and FARMLAND modules will be used to determine the activity concentration in soil (Bq/kg), except for C-14 and tritium which will be assessed using a specific activity model, IAEA-TECDOC-1616, "Quantification of Radionuclide Transfer in Terrestrial and Freshwater Environments for Radiological Assessments," (Reference 9-50). PLUME will model air concentrations for C-14 and tritium. The assessment location will correspond to the area with the highest deposition rates.

## NEDO-34226 Revision C

The activity concentrations will be compared to the out-of-scope values (EPR16 (Reference 9-8), IAEA-TECDOC-1616 (Reference 9-50)) for each radionuclide assessed.

### 9.5.11 Short-Term Dose Assessment

#### 9.5.11.1 Outline

An assessment will be performed to estimate the expected annual dose to a member of the public due to a short-term gaseous discharge during normal operations

A short-term discharge is defined as a release which is larger than a normal release ( $\geq 2\%$  of 12-monthly actual or expected discharges) and which occurs over a relatively short period of time ( $\leq 1$  day). For a normally uniform discharge profile, this equates to about 1 week's discharge being released in 1 day or less (Reference 9-35).

NDAWG provide guidance on short-term release assessments (Reference 9-35) and methodology and examples, "Short-term Releases to the Atmosphere technical methods and examples," (Reference 9-52). Additional methodology is provided in NRPB-W54 "A methodology for Assessing Doses from Short-Term Planned Discharges to Atmosphere," (Reference 9-53). This is the methodology proposed to be followed for the BWRX-300 Stage 3 short-term dose assessment.

#### 9.5.11.2 Short-Term Discharge Source Term

As stated in Section 9.5.4.1 and in NDAWG guidance (Reference 9-35), a short-term assessment is not proposed for a liquid discharge due to the expectation that doses caused by a short-term liquid release will not differ significantly from the dose assessed assuming a continuous liquid release. For this reason, only the impact of a short-term gaseous discharge with a proposed effective release height of 11.7 m will be assessed.

The short-term discharge source term will be based upon an expected event for the BWRX-300 which is a fuel pin failure. In a fuel pin failure, gaseous fission products (e.g., noble gases and iodine) may be released into the reactor coolant along with other particulate and soluble fission products (e.g., caesium). Soluble and particulate species remain in solution and are removed by the reactor water treatment system; however, volatile fission products could be carried over with the steam and are potentially discharged into the environment via the gaseous system. Radioiodine is removed via charcoal beds prior to release, meaning that the short-term discharge is expected to comprise only of noble gas fission products.

There may, however, be other scenarios that would also fit the criteria for a short-term discharge, for example containment purging prior to refuelling. An action has been raised to undertake a systematic review of initiating events that may result in an environmental radiological impact (FAP.PER5-110). Any additional short-term release scenarios identified will be reviewed and confirmed during the more detailed dose assessment, when the associated source terms are available.

#### 9.5.11.3 Modelling Dispersion and Deposition

The Atmospheric Dispersion Modelling Software (ADMS) code "ADMS6," (Reference 9-54) produced by Cambridge Environmental Research Consultants (CERC) is used to calculate the activity concentrations in the plume and the deposition rate for a unit discharge, as well as plume gamma doses.

ADMS6 is a new generation Gaussian plume air dispersion model, characterising the atmospheric boundary layer properties via the boundary layer depth and the Monin-Obukhov length as opposed to the single parameter Pasquill-Gifford class. The software allows flexible input of meteorological data and has options to model aspects such as dry and wet deposition, impacts of hills, variable roughness, buildings and coastlines, short-term releases, and radioactivity decay including gamma dose.

## NEDO-34226 Revision C

ADMS6 is a well-established dispersion modelling code which has been widely used within the UK for applications such as new NPP planning/permitting, stack height studies, and environmental impact assessments. The code has a broad range of users including the UK Environment Agencies, the HSE, and the FSA. In addition, CERC evaluate their codes against available measured data obtained from real world situations, field campaigns, and wind tunnel experiments and publish this data on their website (NRPB-W54 (Reference 9-53) and ADMS6 (Reference 9-54)).

The BWRX-300 short-term dose assessment will be performed for the local resident dwelling and food production locations using general meteorological conditions suitable for a generic site.

### **9.5.11.4 Exposure Pathways and Habit Data**

The short-term discharge is expected to be comprised only of noble gas fission products, which means that the only relevant exposure pathway is submersion in the plume (cloud dose). This is because these radionuclides do not deposit and so do not accumulate in the environment or food-chain. Neither are they absorbed through inhalation into the body resulting in an internal exposure.

Individuals will be assumed to be at the residential location for the duration of the short-term release (24 hours). The indoor and outdoor occupancy will be as defined in the IRAT2 methodology (Reference 9-2) meaning that the adult, child, and infant will be indoors 50%, 80%, and 90% of the time, respectively.

Other assumptions will be made in line with Table 1 of the NDAWG guidance for short-term releases to air (Reference 9-35).

### **9.5.11.5 Short Term Dose Assessment**

Doses will be calculated for the period of the passage of the plume using standard methods. The external dose from immersion in air containing radioactive noble gases will be based on cloud gamma and cloud beta skin dose coefficients which will be taken from DC\_PAK3.02, "Dose Coefficient File Package," (Reference 9-55) and Appendix E of PC-CREAM 08 HPA - RPD-058 (Reference 9-41), respectively.

The estimated short-term doses will be compared to the relevant dose constraints (0.3 mSv and 0.15 mSv), with consideration of the dose also received from a continuous release.

### **9.5.12 Dose Assessment for Non-Human Species**

#### **9.5.12.1 Outline**

The Stage 3 assessment will include a more realistic assessment of the radiological impact on NHS, considering species expected to be present in the marine and terrestrial environments local to the BWRX-300.

#### **9.5.12.2 Dose Assessment Methodology for NHS**

PC-CREAM 08, HPA-RPD-058 (Reference 9-41) will be used to model environmental dispersion of radioactive releases and calculate activity concentrations in the assessed habitats based on the latest source term.

It is proposed to use the Environmental Risks from Ionising Contaminants: Assessment and Management (ERICA) 2.0 tool, "ERICA 2.0 (Environmental Risks from Ionising Contaminants: Assessment and Management)," (Reference 9-56) which calculates dose rates to organisms by applying dose conversion coefficients to the concentrations of radionuclides in environmental media or in biota. ERICA contains reference organisms that complement the reference animals and plants proposed by ICRP, "Environmental Protection – the Concept and Use of Reference Animals and Plants," (Reference 9-57).



## NEDO-34226 Revision C

ERICA 2.0 includes a new dosimetric methodology, to reflect changes presented in ICRP Publication 136, "Dose coefficients for nonhuman biota environmentally exposed to radiation," (Reference 9-58), and revised wildlife concentration factors and associated updated Environmental Media Concentration Limit (EMCL) values.

The ERICA assessment tool consists of three tiers, "ERICA Assessment Tool Help Documentation," (Reference 9-59): an initial screening assessment where, should the pass criteria (dose rate screening value) be met, the user can exit the assessment process; a second tier, where more site specific parameters can be used; and finally a third tier, which consists of a probabilistic risk assessment used when the screening dose criteria are exceeded at Tier 1 and Tier 2.

- Tier 1: a simple and conservative assessment based upon the site description, the radionuclides present, the ecosystem being assessed (e.g., marine, terrestrial), input media concentrations, and time dependent and spatial data. Input media activity concentrations are compared against EMCLs which have been calculated for the most limiting organism for each radionuclide. A risk quotient is produced for each specific radionuclide selected for inclusion in the assessment. If the sum of the risk quotients is  $< 1$  then it can be assured that there is a very low probability that the assessment dose rate to any organism exceeds the incremental screening dose rate and therefore the risk to non-human biota can be considered negligible. If the sum of risk quotients is  $> 1$  then the assessment progresses to Tier 2.
- Tier 2: a more detailed assessment where the user is able to exert more choice in terms of parameter selection. In addition to selecting the radionuclides and reference organisms, the user can also specify their own user-defined geometries and modify default parameters (e.g., concentration ratios, distribution coefficients etc.), to produce a more tailored assessment.
- Tier 3: a probabilistic risk assessment in which uncertainties associated with the results may be determined using sensitivity analysis, and that allows the assessor to access a compilation of up-to-date available scientific literature on the biological effects of exposure to ionising radiation in a number of different species.

### 9.5.13 Uncertainty Assessment

The radiological dose assessment process requires a series of assumptions regarding the discharge, the exposure pathways, and expected human habits, as well as the various parameters specified in the modelling software.

Guidance on how to consider the uncertainty and variability in radiological assessments is provided by NDAWG, "Guidance on considering uncertainty and variability in radiological assessments," (Reference 9-60). If the annual dose to the representative person exceeds 20  $\mu\text{Sv}$  per year, then it is required that the uncertainty and variability in the key assumptions used for the dose assessment are reviewed (Reference 9-19). However, a semi-quantitative review and analysis of identified dose assessment uncertainties will be performed for the BWRX-300 at Stage 3 regardless of the magnitude of the estimated dose.

The uncertainty review will include consideration of the following aspects. This list will be reviewed and extended as new sources of uncertainty are identified or introduced.

- Discharges: comparison of expected discharges and the proposed discharge limits. Consideration of headroom factors, when applied. Consideration of the expected discharge variation for the most radiologically significant radionuclides.
- Marine modelling: choice of PC-CREAM 08 model parameters, particularly those relating to dispersion in the local marine compartment such as the volumetric exchange rate, sediment load, sedimentation rate etc.

### NEDO-34226 Revision C

- Terrestrial modelling: the impact of release height, use of a Gaussian plume model, impact of buildings, impact of meteorological conditions, agricultural practices.
- Exposure pathways: selection of exposure locations for the local resident, for food production and for assessment of direct dose.
- Habits: use of generic habit data NRPB-W41 (Reference 9-44) versus site specific habit data (Reference 9-45).
- Dosimetric data: reliability of dose coefficients, including the chemical form of the discharged radionuclides that these correspond to.
- Other: impact of extended plant operational life, impact of climate change.

## NEDO-34226 Revision C

### 9.6 Conclusion

This chapter presents the results of the BWRX-300 Stage 1 and Stage 2 radiological impact assessment to human and NHS due to liquid and gaseous discharges and direct radiation.

The dose assessment has used the EA IRAT2 tool (Reference 9-1, Reference 9-2) which provides a simple and cautious initial assessment of dose using a screening value of 0.02 mSv.

The results from the dose assessment indicate that the total dose to a representative member of the public from the pathways considered is well below both the source dose constraint of 0.3 mSv/y (Reference 9-8, Reference 9-18, Reference 9-19) and the lower dose constraint of 0.15 mSv recommended for new NPPs (Reference 9-17, Reference 9-19).

The total dose rate to NHS, as represented by the worst affected organisms, is also below the recommended dose rate threshold value of 40  $\mu\text{Gy/h}$ , SC060083/SR1 (Reference 9-22) and the investigation level of 1  $\mu\text{Gy/h}$  (Reference 9-1, Reference 9-2).

A proposed methodology for a more realistic detailed Stage 3 radiological impacts dose assessment has been proposed, using generic habit data NRPB-W41 (Reference 9-44) and more complex modelling tools, HPA-RPD-058 (Reference 9-41).

NEDO-34226 Revision C

**Table 9-1: BWRX-300 Annual Average Liquid Effluent Activity Releases**

| Nuclide | Annual Release (Bq/y*) | Nuclide | Annual Release (Bq/y*) | Nuclide        | Annual Release (Bq/y*) |
|---------|------------------------|---------|------------------------|----------------|------------------------|
| Ag-110m | 2.59E+06               | I-133   | 7.03E+07               | Sr-89          | 1.85E+06               |
| Ba-139  | 8.14E+06               | I-135   | 3.18E+07               | Sr-91          | 7.40E+07               |
| Ba-140  | 1.81E+08               | La-142  | 6.66E+06               | Sr-92          | 1.78E+07               |
| Br-83   | 2.48E+07               | Mn-54   | 2.41E+08               | Tc-99m         | 1.04E+08               |
| Ce-141  | 1.22E+07               | Mn-56   | 7.40E+06               | Te-129m        | 1.85E+07               |
| Ce-143  | 5.92E+06               | Mo-99   | 1.04E+08               | Te-131m        | 7.77E+06               |
| Ce-144  | 8.51E+06               | Na-24   | 7.03E+07               | Te-132         | 2.59E+06               |
| Co-58   | 1.26E+08               | Nb-95   | 4.44E+07               | W-187          | 2.74E+07               |
| Co-60   | 2.44E+08               | Nb-98   | 3.70E+05               | Y-91           | 2.48E+07               |
| Cr-51   | 4.44E+08               | Nd-147  | 1.48E+06               | Y-92           | 5.55E+07               |
| Cs-134  | 8.51E+07               | Ni-63   | 3.70E+06               | Y-93           | 5.92E+06               |
| Cs-136  | 4.81E+07               | Ni-65   | 1.48E+06               | Zn-65          | 9.99E+07               |
| Cs-137  | 1.30E+08               | Np-239  | 7.77E+07               | Zn-69m         | 1.55E+08               |
| Cu-64   | 2.74E+08               | P-32    | 1.74E+07               | Zr-95          | 4.07E+07               |
| Fe-55   | 5.18E+08               | Pr-143  | 2.18E+07               | Zr-97          | 7.40E+05               |
| Fe-59   | 1.30E+08               | Ru-103  | 9.99E+06               |                |                        |
| I-131   | 4.07E+07               | Ru-105  | 2.92E+07               | <b>Total**</b> | <b>3.68E+09</b>        |
| I-132   | 5.55E+06               | Ru-106  | 1.78E+07               |                |                        |

Notes:

\* In converting the 007N1460 (Reference 9-6) Curie activities to Becquerels, it is assumed that 1.0 Ci = 3.7E+10 Bq

\*\*This total activity corresponds to the sum of the annual average liquid effluent release activities by radionuclide as listed in this table, noting that radionuclides with effluent release activities less than 370 kBq/year have not been included in the table or in the total activity calculated.

007N1460 (Reference 9-6)

NEDO-34226 Revision C

**Table 9-2: BWRX-300 Annual Average Gaseous Effluent Activity Releases**

| Nuclide | Annual Release (Bq/y*) | Nuclide | Annual Release (Bq/y) | Nuclide      | Annual Release (Bq/y) |
|---------|------------------------|---------|-----------------------|--------------|-----------------------|
| Ag-110m | 2.40E+04               | Kr-85   | 2.20E+12              | Sr-91        | 1.70E+06              |
| Ar-41   | 3.20E+08               | Kr-85m  | 3.40E+10              | Sr-92        | 1.00E+06              |
| Ba-140  | 7.10E+06               | Kr-87   | 1.20E+11              | Tc-99m       | 2.20E+05              |
| C-14    | 4.00E+11               | Kr-88   | 1.20E+11              | Te-129m      | 8.40E+05              |
| Ce-141  | 4.50E+05               | Kr-89   | 1.20E+13              | Te-131m      | 1.50E+05              |
| Ce-144  | 7.20E+04               | La-140  | 1.60E+06              | Te-132       | 6.80E+04              |
| Co-58   | 5.20E+06               | Mn-54   | 1.20E+07              | W-187        | 5.30E+05              |
| Co-60   | 1.10E+07               | Mn-56   | 4.50E+05              | Xe-131m      | 3.80E+10              |
| Cr-51   | 2.00E+07               | Mo-99   | 2.60E+06              | Xe-133       | 1.60E+12              |
| Cs-134  | 6.60E+05               | Na-24   | 1.40E+06              | Xe-133m      | 1.10E+09              |
| Cs-136  | 3.70E+05               | Nb-95   | 1.80E+06              | Xe-135       | 1.30E+12              |
| Cs-137  | 1.00E+06               | Ni-63   | 2.50E+04              | Xe-135m      | 1.20E+12              |
| Cs-138  | 1.10E+05               | Np-239  | 1.80E+06              | Xe-137       | 1.70E+12              |
| Cu-64   | 5.80E+06               | P-32    | 6.90E+05              | Xe-138       | 2.40E+12              |
| Fe-55   | 2.40E+07               | Pr-144  | 8.40E+01              | Y-90         | 8.80E+02              |
| Fe-59   | 5.80E+06               | Rb-89   | 4.40E+04              | Y-91         | 8.90E+05              |
| H-3     | 9.70E+11               | Rh-103m | 1.90E+03              | Y-92         | 4.10E+05              |
| I-131   | 5.20E+08               | Rh-106  | 1.00E+04              | Y-93         | 1.30E+05              |
| I-132   | 3.10E+09               | Ru-103  | 4.50E+05              | Zn-65        | 4.90E+06              |
| I-133   | 2.40E+09               | Ru-106  | 7.30E+04              | Zr-95        | 1.90E+06              |
| I-134   | 8.70E+09               | Sb-124  | 4.90E+02              |              |                       |
| I-135   | 4.60E+09               | Sr-89   | 8.00E+04              | <b>Total</b> | <b>2.44E+13</b>       |
| Kr-83m  | 3.30E+11               | Sr-90   | 3.60E+03              |              |                       |

Notes:

\* In converting the 007N1078 (Reference 9-31) Curies activities to Becquerels, a conversion of

1.0 Ci = 3.7E+10 Bq has been applied

007N1078 (Reference 9-31)

NEDO-34226 Revision C

**Table 9-3: Summary of Operational BWR Reported TLD Data from the 2023 USNRC Environmental Reports**

| Station               | 2023 Dose (engineering judgement* of reported dose or dose range) | Annual Dose (based on maximum) | Annual Dose $\mu\text{Sv}^{**}$ | Dose rate $\mu\text{Sv/h}$ | Annual Dose $\mu\text{Sv}$ (occupancy of 104 h/y) |
|-----------------------|---|--------------------------------|---------------------------------|----------------------------|---|
| Browns Ferry 1, 2 & 3 | 15-22 mrem/std. qtr   | 88 mrem                        | 880                             | 0.10                       | 10.4  |
| Brunswick 1 & 2       | 10 mR/std. qtr  | 40 mR                          | 400                             | 0.05                       | 4.7   |
| Clinton               | 19-21 mrem/std. qtr   | 84 mrem                        | 840                             | 0.10                       | 10.0  |
| Columbia              | 0.28-0.34 mR/day  | 124 mR                         | 1240                            | 0.14                       | 14.7  |
| Cooper                | 20 mR/qtr   | 80 mR                          | 800                             | 0.09                       | 9.5   |
| Dresden 2&3           | 7.6-24.0 mrem/qtr   | 96 mrem                        | 960                             | 0.11                       | 11.4  |
| Edwin Hatch 1 & 2     | 10-13 mR/qtr  | 52 mrem                        | 520                             | 0.06                       | 6.2   |
| Fermi 2               | 11-19 mR/std. qtr   | 76 mR                          | 760                             | 0.09                       | 9.0   |
| Grand Gulf 1          | 10 mR/qtr   | 40 mR                          | 400                             | 0.05                       | 4.7   |
| Hope Creek 1          | 15 mR/qtr   | 60 mR                          | 600                             | 0.07                       | 7.1   |
| James A Fitzpatrick   | 4-5.7 mrem/std month  | 68 mrem                        | 680                             | 0.08                       | 8.1   |
| La Salle County 1 & 2 | 75 mrem/year  | 75 mrem                        | 750                             | 0.09                       | 8.9   |
| Limerick 1 & 2        | 12-28 mrem/qtr  | 112 mrem                       | 1120                            | 0.13                       | 13.3  |
| Monticello            | 10-16 mrem/std. qtr   | 64 mrem                        | 640                             | 0.07                       | 7.6   |
| Nine Mile Point 1 & 2 | 5 mrem / std. month   | 60 mrem                        | 600                             | 0.07                       | 7.1   |
| Peach Bottom 2 & 3    | 100 mrem/year   | 100 mrem                       | 1000                            | 0.11                       | 11.9  |
| Perry 1               | 14 mrem/qtr   | 56 mrem                        | 560                             | 0.06                       | 6.6   |
| Quad Cities 1 & 2     | 30 mrem/year  | 30 mrem                        | 300                             | 0.03                       | 3.6   |
| River Bend 1          | 11-17 mrem/std. qtr   | 68 mrem                        | 680                             | 0.08                       | 8.1   |
| Susquehanna 1& 2      | 15-17 mrem/std. qtr   | 68 mrem                        | 680                             | 0.08                       | 8.1   |
| <b>Average</b>        |   |                                |                                 | <b>0.08</b>                | <b>8.6</b>  |

Notes:

\* Engineering judgement of the typical range of reported values, excluding outliers

\*\* a conversion of 1 mR = 1 mrem = 0.01 mSv = 10  $\mu\text{Sv}$  has been applied, noting that this is rounded up for mR  
 "Radioactive Effluent and Environmental Reports," (Reference 9-33)

NEDO-34226 Revision C

**Table 9-4: Sites Potentially Suitable for Deployment of a New Nuclear Power Station and Their Coastal Exchange Rate**

| Site Location | Coastal Exchange Rate m <sup>3</sup> /s |
|---------------|---|
| Bradwell      | 231                                     |
| Hartlepool    | 634                                     |
| Heysham       | 634                                     |
| Hinkley Point | 634                                     |
| Oldbury       | 570                                     |
| Sizewell      | 444                                     |
| Sellafield    | 3170                                    |
| Wylfa         | 1010                                    |

Note:

LIT 15793 (Reference 9-27)



NEDO-34226 Revision C

**Table 9-5: Liquid Discharge: Radionuclides Without a DPUR,  
 Origin and Proposed Surrogate**

| Nuclide | Fission product? | Surrogate | Nuclide | Fission product? | Surrogate |
|---------|------------------|-----------|---------|------------------|-----------|
| Ba-139  | Yes              | Cs-137    | Sr-91   | Yes              | Cs-137    |
| Br-83   | Yes              | Cs-137    | Sr-92   | Yes              | Cs-137    |
| Ce-143  | Yes              | Cs-137    | Te-129m | Yes              | Cs-137    |
| I-132   | Yes              | Cs-137    | Te-131m | Yes              | Cs-137    |
| La-142  | Yes              | Cs-137    | Te-132  | Yes              | Cs-137    |
| Mn-56   | No               | Pb-212    | W-187   | No               | Pb-212    |
| Nb-98   | Yes              | Cs-137    | Y-91    | Yes              | Cs-137    |
| Nd-147  | Yes              | Cs-137    | Y-92    | Yes              | Cs-137    |
| Ni-65   | No               | Pb-212    | Y-93    | Yes              | Cs-137    |
| Np-239  | No               | Mn-52     | Zn-69m  | No               | Pb-212    |
| Pr-143  | Yes              | Cs-137    | Zr-97   | Yes              | Cs-137    |
| Ru-105  | Yes              | Cs-137    |         |                  |           |

NEDO-34226 Revision C

**Table 9-6: Liquid Discharge: Radionuclides Without a DPUR, Categories for Stage 2 IRAT2 Modelling**

| Category            | Scenario 1 Bq/y | Scenario 2 Bq/y | Scenario 3 Bq/y |
|---------------------|-----------------|-----------------|-----------------|
| Mn-52               | 0               | 7.77E+07        | 7.81E+06        |
| Cs-137              | 0               | 4.42E+08        | 4.44E+07        |
| (true Cs-137 only*) | 0               | 1.30E+08        | 1.31E+07        |
| Pb-212              | 0               | 1.91E+08        | 1.92E+07        |

Note:

\* For comparison, this is the activity of true Cs-137 as declared in the BWRX-300 liquid discharge source term, see Table 9-1

NEDO-34226 Revision C

**Table 9-7: Gaseous Discharge: Radionuclides Without a DPUR,  
 Origin and Proposed Surrogate**

| Nuclide | Fission product? | Surrogate   | Nuclide | Fission product? | Surrogate   |
|---------|------------------|-------------|---------|------------------|-------------|
| Cs-138  | Yes              | Cs-137      | Te-129m | Yes              | Cs-137      |
| Kr-83m  | Noble gas        | See 9.3.4.2 | Te-131m | Yes              | Cs-137      |
| Kr-87   | Noble gas        | See 9.3.4.2 | Te-132  | Yes              | Cs-137      |
| Kr-88   | Noble gas        | See 9.3.4.2 | W-187   | No               | Pb-212      |
| Kr-89   | Noble gas        | See 9.3.4.2 | Xe-131m | Noble gas        | See 9.3.4.2 |
| Np-239  | No               | Mn-52       | Xe-133m | Noble gas        | See 9.3.4.2 |
| Pr-144  | Yes              | Cs-137      | Xe-135  | Noble gas        | See 9.3.4.2 |
| Rb-89   | Yes              | Cs-137      | Xe-135m | Noble gas        | See 9.3.4.2 |
| Rh-103m | Yes              | Cs-137      | Xe-137  | Noble gas        | See 9.3.4.2 |
| Rh-106  | Yes              | Cs-137      | Xe-138  | Noble gas        | See 9.3.4.2 |
| Sb-124  | Yes              | Cs-137      | Y-91    | Yes              | Cs-137      |
| Sr-91   | Yes              | Cs-137      | Y-92    | Yes              | Cs-137      |
| Sr-92   | Yes              | Cs-137      | Y-93    | Yes              | Cs-137      |

NEDO-34226 Revision C

**Table 9-8: Gaseous Discharge: Radionuclides Without a DPUR,  
 Categories for Stage 2 IRAT2 Modelling**

| Category                  | Noble Gases modelled as<br>Xe-133 Bq/y | Noble Gases modelled as<br>Kr-88 Bq/y |
|---------------------------|--|---------------------------------------|
| Mn-52                     | 1.80E+06                               | 1.80E+06                              |
| Kr-88                     | -                                      | 1.92E+13                              |
| (true Kr-88 only*)        | -                                      | 1.20E+11                              |
| Xe-133 (including Xe-133) | 2.08E+13                               | -                                     |
| (true Xe-133 only*)       | 1.60E+12                               | -                                     |
| Cs-137 (including Cs-137) | 6.35E+06                               | 6.35E+06                              |
| (true Cs-137 only*)       | 1.00E+06                               | 1.00E+06                              |
| Pb-212                    | 5.30E+05                               | 5.30E+05                              |

Note:

\* For comparison, this is the activity of true Cs-137, true Kr-88 and true Xe-133 as declared in the BWRX-300 gaseous discharge source term, see Table 9-2.

NEDO-34226 Revision C

**Table 9-9: Estimated Stage 1 Dose to the Representative Person (Liquid Discharge)**

| Scenario | Description  | External Dose<br>μSv/y | Food Dose<br>μSv/y | Total Dose<br>μSv/y |
|----------|--|------------------------|--------------------|---------------------|
| 1        | Zero annual liquid discharge   | 0.0                    | 0.0                | 0.0                 |
| 2        | Full annual liquid discharge plus tritium at reactor coolant concentrations (H-3 = 3.10E+12 Bq/y).   | 3.8                    | 1.8                | 5.5                 |
| 3        | Nominal annual liquid discharge, proposed as a discharge volume of 600 m <sup>3</sup> /y. Scenario 2 activities scaled by a factor of 0.101. | 0.38                   | 0.18               | 0.55                |

NEDO-34226 Revision C

**Table 9-10: Breakdown of Stage 1 Scenario 2 Dose to the Representative Person by Radionuclide (Liquid Discharge)**

| Radionuclide     | External dose<br>$\mu\text{Sv/y}$ | Fish / shellfish<br>dose $\mu\text{Sv/y}$ | Total dose<br>$\mu\text{Sv/y}$ | % Contribution |
|------------------|-----------------------------------|---|--------------------------------|----------------|
| Co-60            | 2.9E+00                           | 4.9E-02                                   | 3.0E+00                        | 54.0%          |
| Zn-65            | 4.2E-02                           | 9.0E-01                                   | 9.4E-01                        | 17.0%          |
| P-32             | 1.5E-08                           | 6.7E-01                                   | 6.7E-01                        | 12.2%          |
| Other beta/gamma | 3.3E-01                           | 5.2E-02                                   | 3.8E-01                        | 6.9%           |
| Mn-54            | 2.5E-01                           | 2.9E-03                                   | 2.5E-01                        | 4.6%           |
| Cs-137           | 7.3E-02                           | 1.2E-02                                   | 8.5E-02                        | 1.5%           |
| Tritium          | 0.0E+00                           | 9.3E-03                                   | 9.3E-03                        | 0.2%           |

NEDO-34226 Revision C

**Table 9-11: Breakdown of Stage 1 Scenario 3 Dose to the Representative Person by Radionuclide (Liquid Discharge)**

| Radionuclide     | External dose<br>μSv/y | Fish / shellfish<br>dose μSv/y | Total dose<br>μSv/y | % Contribution |
|------------------|------------------------|--------------------------------|---------------------|----------------|
| Co-60            | 2.9E-01                | 4.9E-03                        | 3.0E-01             | 54.0%          |
| Zn-65            | 4.2E-03                | 9.0E-02                        | 9.5E-02             | 17.0%          |
| P-32             | 1.5E-09                | 6.8E-02                        | 6.8E-02             | 12.2%          |
| Other beta/gamma | 3.3E-02                | 5.3E-03                        | 3.8E-02             | 6.9%           |
| Mn-54            | 2.5E-02                | 3.0E-04                        | 2.5E-02             | 4.6%           |
| Cs-137           | 7.4E-03                | 1.2E-03                        | 8.6E-03             | 1.5%           |
| Tritium          | 0.0E+00                | 9.4E-04                        | 9.4E-04             | 0.2%           |



NEDO-34226 Revision C

**Table 9-12: Estimated Stage 1 Dose to the Representative Person  
(Gaseous Discharge)**

| Scenario | Description                    | Inhalation<br>Dose<br>$\mu\text{Sv/y}$ | External<br>Dose<br>$\mu\text{Sv/y}$ | Food<br>Dose<br>$\mu\text{Sv/y}$ | Total<br>Dose<br>$\mu\text{Sv/y}$ |
|----------|--------------------------------|--|--------------------------------------|----------------------------------|-----------------------------------|
| 1        | Noble gases modelled as Xe-133 | 16.0                                   | 2.0                                  | 16.0                             | 34.0                              |
| 2        | Noble gases modelled as Kr-88  | 15.5                                   | 96.7                                 | 16.1                             | 128.2                             |

NEDO-34226 Revision C

**Table 9-13: Breakdown of Stage 1 Dose to the Representative Person by Radionuclide  
(Gaseous Discharge – Noble Gases as Xe-133)**

| Radionuclide | Inhalation<br>dose<br>$\mu\text{Sv/y}$ | External<br>dose<br>$\mu\text{Sv/y}$ | Fish /<br>shellfish<br>dose $\mu\text{Sv/y}$ | Total<br>dose<br>$\mu\text{Sv/y}$ | %<br>Contribution |
|--------------|--|--------------------------------------|--|-----------------------------------|-------------------|
| C-14         | 1.4E+01                                | 2.6E-05                              | 1.4E+01                                      | 2.8E+01                           | 83.2%             |
| I-131        | 1.8E-01                                | 2.0E-02                              | 2.1E+00                                      | 2.3E+00                           | 6.9%              |
| Xe-133       | 0.0E+00                                | 1.5E+00                              | 0.0E+00                                      | 1.5E+00                           | 4.4%              |
| Tritium      | 6.9E-01                                | 0.0E+00                              | 2.7E-01                                      | 9.5E-01                           | 2.8%              |
| I-133        | 2.1E-01                                | 1.8E-02                              | 1.5E-01                                      | 3.8E-01                           | 1.1%              |

NEDO-34226 Revision C

**Table 9-14: Breakdown of Stage 1 Dose to the Representative Person by Radionuclide  
 (Gaseous Discharge – Noble Gases as Kr-88)**

| Radionuclide | Inhalation dose $\mu\text{Sv/y}$ | External dose $\mu\text{Sv/y}$ | Terrestrial food dose $\mu\text{Sv/y}$ | Total dose $\mu\text{Sv/y}$ | % Contribution |
|--------------|----------------------------------|--------------------------------|--|-----------------------------|----------------|
| C-14         | 1.4E+01                          | 2.6E-05                        | 1.4E+01                                | 2.8E+01                     | 21.8%          |
| Kr-88        | 0.0E+00                          | 9.6E+01                        | 0.0E+00                                | 9.6E+01                     | 74.9%          |
| I-131        | 1.8E-01                          | 2.0E-02                        | 2.1E+00                                | 2.3E+00                     | 1.8%           |

Notes:

\* Kr-88 includes the noble gases without an IRAT2 DPUR (Kr-83m, Kr-87, Kr-88, Kr-89, Xe-131m, Xe - 133m, Xe-135m, Xe-135, Xe-137, Xe-138)

NEDO-34226 Revision C

**Table 9-15: Stage 1 Assessment – Total Dose to the Representative Person**

| Discharge route                                    | Estimated dose (as Xe-133) $\mu\text{Sv/y}$ | Estimated dose (as Kr-88) $\mu\text{Sv/y}$ |
|--|---|--|
| Liquid discharge (Scenario 2)                      | 5.5   | 5.5  |
| Gaseous Discharge (noble gases modelled as Xe-133) | 34.0  | -  |
| Gaseous Discharge (noble gases modelled as Kr-88)  | -   | 128.2                                      |
| Direct Radiation                                   | 8.6   | 8.6  |
| <b>Total</b>                                       | <b>48.1</b>                                 | <b>142.3</b>                               |

NEDO-34226 Revision C

**Table 9-16: Estimated Stage 2 Dose to the Representative Person (Liquid Discharge)**

| Scenario | Description  | External Dose<br>μSv/y | Food Dose<br>μSv/y | Total Dose<br>μSv/y |
|----------|--|------------------------|--------------------|---------------------|
| 1        | Zero annual liquid discharge   | 0.0                    | 0.0                | 0.0                 |
| 2        | Full annual liquid discharge plus tritium at reactor coolant concentrations (H-3 = 3.10E+12 Bq/y).   | 0.47                   | 0.24               | 0.71                |
| 3        | Nominal annual liquid discharge, proposed as a discharge volume of 600 m <sup>3</sup> /y. Scenario 2 activities scaled by a factor of 0.101. | 0.047                  | 0.024              | 0.071               |

NEDO-34226 Revision C

**Table 9-17: Breakdown of Stage 2 Scenario 2 Dose to the Representative Person by Radionuclide (Liquid Discharge)**

| Radionuclide | External dose<br>μSv/y | Fish / shellfish<br>dose μSv/y | Total dose<br>μSv/y | % Contribution |
|--------------|------------------------|--------------------------------|---------------------|----------------|
| Co-60        | 3.8E-01                | 6.3E-03                        | 3.9E-01             | 54.8%          |
| Zn-65        | 5.4E-03                | 1.2E-01                        | 1.2E-01             | 17.3%          |
| P-32         | 1.9E-09                | 8.7E-02                        | 8.7E-02             | 12.4%          |
| Cs-137*      | 3.2E-02                | 5.2E-03                        | 3.8E-02             | 5.3%           |
| Mn-54        | 3.3E-02                | 3.8E-04                        | 3.3E-02             | 4.7%           |
| Pb-212**     | 1.4E-06                | 1.2E-02                        | 1.2E-02             | 1.7%           |
| Tritium      | 0.0E+00                | 1.2E-03                        | 1.2E-03             | 0.2%           |

Notes:

\* Cs-137 now also includes other fission products

\*\* Pb-212 is a surrogate radionuclide



NEDO-34226 Revision C

**Table 9-18: Breakdown of Stage 2 Scenario 3 Dose to the Representative Person by Radionuclide (Liquid Discharge)**

| Radionuclide | External dose<br>$\mu\text{Sv/y}$ | Fish / shellfish<br>dose $\mu\text{Sv/y}$ | Total dose<br>$\mu\text{Sv/y}$ | % Contribution |
|--------------|-----------------------------------|---|--------------------------------|----------------|
| Co-60        | 3.8E-02                           | 6.4E-04                                   | 3.9E-02                        | 54.8%          |
| Zn-65        | 5.4E-04                           | 1.2E-02                                   | 1.2E-02                        | 17.2%          |
| P-32         | 1.9E-10                           | 8.8E-03                                   | 8.8E-03                        | 12.4%          |
| Cs-137*      | 3.2E-03                           | 5.2E-04                                   | 3.8E-03                        | 5.3%           |
| Mn-54        | 3.3E-03                           | 3.8E-05                                   | 3.3E-03                        | 4.7%           |
| Pb-212**     | 1.4E-07                           | 1.2E-03                                   | 1.2E-03                        | 1.7%           |
| Tritium      | 0.0E+00                           | 1.2E-04                                   | 1.2E-04                        | 0.2%           |

Notes:

\* Cs-137 now also includes other fission products

\*\* Pb-212 is a surrogate radionuclide

NEDO-34226 Revision C

**Table 9-19: Estimated Stage 2 Dose to the Representative Person  
(Gaseous Discharge)**

| Scenario | Description                    | Inhalation<br>Dose<br>$\mu\text{Sv/y}$ | External<br>Dose<br>$\mu\text{Sv/y}$ | Food<br>Dose<br>$\mu\text{Sv/y}$ | Total<br>Dose<br>$\mu\text{Sv/y}$ |
|----------|--------------------------------|--|--------------------------------------|----------------------------------|-----------------------------------|
| 1        | Noble gases modelled as Xe-133 | 1.1                                    | 0.1                                  | 10.0                             | 11.2                              |
| 2        | Noble gases modelled as Kr-88  | 1.1                                    | 6.8                                  | 10.3                             | 18.2                              |

NEDO-34226 Revision C

**Table 9-20: Breakdown of Stage 2 Dose to the Representative Person by Radionuclide  
(Gaseous Discharge – Noble Gases as Xe-133)**

| Radionuclide | Inhalation<br>dose $\mu\text{Sv/y}$ | External<br>dose $\mu\text{Sv/y}$ | Terrestrial<br>food dose<br>$\mu\text{Sv/y}$ | Total dose<br>$\mu\text{Sv/y}$ | %<br>Contribution |
|--------------|-------------------------------------|-----------------------------------|--|--------------------------------|-------------------|
| C-14         | 1.0E+00                             | 1.8E-06                           | 8.7E+00                                      | 9.7E+00                        | 84.0%             |
| I-131        | 1.3E-02                             | 1.4E-03                           | 1.3E+00                                      | 1.4E+00                        | 11.9%             |
| Tritium      | 4.8E-02                             | 0.0E+00                           | 1.7E-01                                      | 2.2E-01                        | 1.9%              |

NEDO-34226 Revision C

**Table 9-21: Breakdown of Stage 2 Dose to the Representative Person by Radionuclide  
 (Gaseous Discharge – Noble Gases as Kr-88)**

| Radionuclide | Inhalation dose<br>μSv/y | External dose<br>μSv/y | Terrestrial food dose<br>μSv/y | Total dose<br>μSv/y | % Contribution |
|--------------|--------------------------|------------------------|--------------------------------|---------------------|----------------|
| C-14         | 1.0E+00                  | 1.8E-06                | 8.7E+00                        | 9.7E+00             | 53.1%          |
| Kr-88*       | 0.0E+00                  | 6.7E+00                | 0.0E+00                        | 6.7E+00             | 36.9%          |
| I-131        | 1.3E-02                  | 1.4E-03                | 1.3E+00                        | 1.4E+00             | 7.5%           |
| H-3          | 4.8E-02                  | 0.0E+00                | 1.7E-01                        | 2.2E-01             | 1.2%           |

Notes:

\* Kr-88 includes the noble gases without an IRAT2 DPUR (Kr-83m, Kr-87, Kr-88, Kr-89, Xe-131m, Xe - 133m, Xe-135m, Xe-135, Xe-137, Xe-138)

NEDO-34226 Revision C

**Table 9-22: Stage 2 Assessment – Total Dose to the Representative Person**

| Discharge route                                    | Estimated dose<br>(as Xe-133) $\mu\text{Sv/y}$ | Estimated dose<br>(as Kr-88) $\mu\text{Sv/y}$ |
|--|--|---|
| Liquid discharge (Scenario 2)                      | 0.71   | 0.71  |
| Gaseous Discharge (noble gases modelled as Xe-133) | 11.2   | -   |
| Gaseous Discharge (noble gases modelled as Kr-88)  | -  | 18.2  |
| Direct Radiation                                   | 8.6  | 8.6   |
| <b>Total</b>                                       | <b>20.5</b>                                    | <b>27.5</b>                                   |

## NEDO-34226 Revision C

### 9.7 References

- 9-1 "Initial Radiological Assessment Tool 2: Part 1 User Guide," Chief Scientist's Group Report, Environment Agency, November 2022. Available at [https://assets.publishing.service.gov.uk/media/63528534d3bf7f1943006c5f/Initial\\_radiological\\_assessment\\_tool\\_2\\_-\\_part\\_1\\_user\\_guide.pdf](https://assets.publishing.service.gov.uk/media/63528534d3bf7f1943006c5f/Initial_radiological_assessment_tool_2_-_part_1_user_guide.pdf).
- 9-2 "Initial Radiological Assessment Tool 2: Part 2 Methods and Input Data," Chief Scientist's Group report, Environment Agency, November 2022. Available at [https://assets.publishing.service.gov.uk/media/63528573d3bf7f1943006c60/Initial\\_radiological\\_assessment\\_tool\\_2\\_-\\_part\\_2\\_methods\\_and\\_input\\_data.pdf](https://assets.publishing.service.gov.uk/media/63528573d3bf7f1943006c60/Initial_radiological_assessment_tool_2_-_part_2_methods_and_input_data.pdf).
- 9-3 NEDO-34219, "BWRX-300 UK GDA Chapter E2: Generic Site Description," Rev B, GE-Hitachi Nuclear Energy, Americas, LLC.
- 9-4 NEDO-34223, "BWRX-300 UK GDA Chapter E6: Demonstration of BAT Approach," Rev B, GE-Hitachi Nuclear Energy, Americas, LLC.
- 9-5 "New Nuclear Power Plants: Generic Design Assessment Guidance for Requesting Parties," Environment Agency, Natural Resources Wales, Office for Nuclear Regulation, October 2023. Available at <https://www.gov.uk/government/publications/new-nuclear-power-plants-generic-design-assessment-guidance-for-requesting-parties>
- 9-6 007N1460, "BWRX-300 Annual Average Liquid Effluent Activity Releases," Rev 3, GE-Hitachi Nuclear Energy, May 2023.
- 9-7 NEDO-34224, "BWRX-300 UK GDA Chapter E7: Radioactive Discharges," Rev B, GE-Hitachi Nuclear Energy, Americas, LLC.
- 9-8 "The Environmental Permitting (England and Wales) Regulations 2016" (as amended), SI 2016 No 1154, UK Government. Available at <https://www.legislation.gov.uk/uksi/2016/1154/contents/made>
- 9-9 NEDO-34175, "BWRX-300 UK GDA Chapter 12: Radiation Protection," Rev B, GE-Hitachi Nuclear Energy, Americas, LLC.
- 9-10 "1990 Recommendations of the International Commission on Radiological Protection," ICRP Publication 60. Ann ICRP, 21, 1-3., ICRP, 1991. Available at [https://journals.sagepub.com/doi/pdf/10.1177/ANIB\\_21\\_1-3](https://journals.sagepub.com/doi/pdf/10.1177/ANIB_21_1-3)
- 9-11 "Council Directive 96/29/Euratom of 13 May 1996 Laying Down Basic Safety Standards for the Protection of the Health of Workers and the General Public Against the Dangers Arising from Ionizing Radiation," Official Journal of the European Communities, L159, Volume 39, 29 June 1996. Available at [https://www.legislation.gov.uk/eudr/1996/29/pdfs/eudr\\_19960029\\_2000-05-13\\_en.pdf](https://www.legislation.gov.uk/eudr/1996/29/pdfs/eudr_19960029_2000-05-13_en.pdf)
- 9-12 "The 2007 Recommendations of the International Commission on Radiological Protection," ICRP Publication 103. Ann ICRP, 37, 2-4., ICRP, 2007. Available at [https://journals.sagepub.com/doi/pdf/10.1177/ANIB\\_37\\_2-4](https://journals.sagepub.com/doi/pdf/10.1177/ANIB_37_2-4)
- 9-13 "Council Directive 2013/59/Euratom of 5 December 2013 Laying Down Basic Safety Standards for Protection Against the Dangers Arising From Exposure To Ionising Radiation, and Repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom," Official Journal of the European Union L13/1, 17 January 2014. Available at <https://www.legislation.gov.uk/eudr/2013/59/contents>
- 9-14 "The Ionising Radiations Regulations 2017," UK Statutory Instruments 2017 No. 1075. Available at <https://www.legislation.gov.uk/uksi/2017/1075/contents/made> (Accessed June 2025).



NEDO-34226 Revision C

- 9-15 "The Environmental Authorisations (Scotland) Regulations 2018," Scottish Statutory Instruments 2018 No. 219. Available at <https://www.legislation.gov.uk/ssi/2018/219/contents/made> (Accessed June 2025).
- 9-16 "The Radioactive Substances (Modification of Enactments) Regulations (Northern Ireland) 2018," Northern Ireland Statutory Rules, 2018 No.116. Available at <https://www.legislation.gov.uk/nisr/2018/116/contents/made> (Accessed June 2025).
- 9-17 RCE-12, "Application of the 2007 Recommendations of the ICRP to the UK," Advice from the Health Protection Agency, Document of the Health Protection Agency, Radiation, Chemical and Environmental Hazards, July 2009. Available at [https://assets.publishing.service.gov.uk/media/5a7e2c0540f0b62302689a19/RCE-12\\_for\\_website\\_v2.pdf](https://assets.publishing.service.gov.uk/media/5a7e2c0540f0b62302689a19/RCE-12_for_website_v2.pdf)
- 9-18 CM2919, "Review of Radioactive Waste Management Policy Final Conclusions," July 1995. Available at [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/829274/review-radioactive-waste-management-policy-cm2919.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/829274/review-radioactive-waste-management-policy-cm2919.pdf)
- 9-19 "Principles for the Assessment of Prospective Public Doses arising from Authorised Discharges of Radioactive Waste to the Environment," Radioactive Substances Regulation under the Radioactive Substances Act (RSA-93) or under the Environmental Permitting Regulations (EPR-10), August 2012. Available at [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/296390/geho1202bklh-e-e.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/296390/geho1202bklh-e-e.pdf)
- 9-20 "Criteria for setting limits on the discharge of radioactive waste from nuclear sites," Version 1.0, Environment Agency, June 2012. Available at <https://assets.publishing.service.gov.uk/media/5a7ca08ced915d12ab4bc0f1/geho0612buqp-e-e.pdf>
- 9-21 006N5081, "BWRX-300 As Low as Reasonably Achievable Design Criteria for Standard Design," Rev 0, GE-Hitachi Nuclear Energy, Americas. LLC, August 2024.
- 9-22 SC060083/SR1, "Habitats assessment for radioactive substances," Better regulation science programme, Science report, Environment Agency, 2009. Available at <https://assets.publishing.service.gov.uk/media/5a7c50a6e5274a2041cf32da/scho0309bpml-e-e.pdf>
- 9-23 EPG-RSR-B3, "How to apply for an environmental permit Part RSR-3 – New bespoke radioactive substances activity permit nuclear site – unsealed sources and radioactive waste," Guidance Notes, Version 5, Environment Agency, January 2022. Available at <https://assets.publishing.service.gov.uk/media/621c7baa8fa8f54916f45f68/Form-guidance-Part-RSR-B3-Nuclear-site.pdf>
- 9-24 "Radioactive substances regulation (RSR): objective and principles," Environment Agency, December 2021. Available at <https://www.gov.uk/government/publications/radioactive-substances-regulation-rsr-objective-and-principles/radioactive-substances-regulation-rsr-objective-and-principles>
- 9-25 "RSR generic developed principles: regulatory assessment," Environment Agency, 2021. Available at <https://www.gov.uk/government/publications/rsr-generic-developed-principles-regulatory-assessment>
- 9-26 "Guidance on initial/simple assessment tools," NDAWG Guidance Note 2, Version 1.0 Final, 2008. Available at [https://www.ukhsa-protectionservices.org.uk/cms/assets/gfx/content/resource\\_4609cse661551c8e.pdf](https://www.ukhsa-protectionservices.org.uk/cms/assets/gfx/content/resource_4609cse661551c8e.pdf)

NEDO-34226 Revision C

- 9-27 LIT 15793, "Initial radiological assessment tool - estuary\_coast," Version 6, Environment Agency, December 2022.
- 9-28 LIT 15791, "Initial radiological assessment tool – air," Version 4, Environment Agency, May 2022.
- 9-29 LIT 15792, "Initial radiological assessment tool – river," Version 6, Environment Agency, May 2022.
- 9-30 LIT 15794, "Initial radiological assessment tool – sewer," Version 9, Environment Agency, January 2023.
- 9-31 007N1078, "Annual Average Gaseous Effluent Releases for the BWRX-300 Standard Plant," Rev 2, GEH, June 2023.
- 9-32 NUREG-0016, "Calculation of Release of Radioactive Materials in Gaseous and Liquid Effluents from Boiling-Water Reactors: GALE-BWR 3.2 Code," Revision 2, U.S. NRC, July 2020. Available at <https://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr0016/r2/index.html>
- 9-33 "Radioactive Effluent and Environmental Reports," United States Nuclear Regulatory Commission. Available at <https://www.nrc.gov/reactors/operating/ops-experience/tritium/plant-info.html> (Accessed June 2025).
- 9-34 GA91-9901-0025-00001, "UKABWR Generic Design Assessment Quantification of Discharges and Limits," Rev G, Hitachi-GE, 2017. Available at <http://www.hitachi-hgne-uk-abwr.co.uk/downloads/2017-12-14/%5bE07%5dUKABWR-GA91-9901-0025-00001-RevG-PUB.pdf>
- 9-35 "Guidance on short term release assessments," NDAWG Guidance Note 6B, June 2020. Available at [https://www.ukhsa-protectionservices.org.uk/cms/assets/gfx/content/resource\\_4624cs9d8df73a3c.pdf](https://www.ukhsa-protectionservices.org.uk/cms/assets/gfx/content/resource_4624cs9d8df73a3c.pdf)
- 9-36 005N4258, "BWRX-300 Coolant Radiation Concentrations," Rev 2, GE-Hitachi Nuclear Energy, April 2023.
- 9-37 SMR0004490, "E3S Case Chapter 30: Prospective radiological assessment," Issue 2, Rolls Royce SMR, 2023. Available at <https://gda.rolls-royce-smr.com/assets/documents/documents/rr-smr-e3s-case-chapter-30-prospective-radiological-assessment---issue-2-gda-publication.pdf>
- 9-38 HPR/GDA/PCER/0007, "Pre-Construction Environmental Report Chapter 07 Radiological Assessment," Rev 002, UK HPR1000 GDA, General Nuclear System Ltd., 2021. Available at <https://ukhpr1000.co.uk/wp-content/uploads/2018/11/HPR-GDA-PCER-0007-Pre-Construction-Environmental-Report-Chapter-7-Radiological-Assessment.pdf>
- 9-39 NRPB-R157, "The Fifth Report of a Working Group on Atmospheric Dispersion, Models to Allow for the Effects of Coastal Sites, Plume Rise and Buildings on Dispersion of Radionuclides and Guidance on the Value of Deposition Velocity and Washout Coefficients," National Radiological Protection Board, 1983.
- 9-40 005N9751, "BWRX-300 General Description," Rev F, GE-Hitachi Nuclear Energy Americas LLC, December 2023.
- 9-41 HPA-RPD-058, "The Methodology for Assessing the Radiological Consequences of Routine Releases of Radionuclides to the Environment Used in PC-CREAM 08," Version 1.1, J G Smith and J R Simmond, Health Protection Agency, November 2009. Available at [https://assets.publishing.service.gov.uk/media/5a8017c040f0b6230269177c/HPA-RPD-058\\_June\\_2015.pdf](https://assets.publishing.service.gov.uk/media/5a8017c040f0b6230269177c/HPA-RPD-058_June_2015.pdf)

NEDO-34226 Revision C

- 9-42 UKHSA-RCE-004, "Verification and validation of models used in radiological assessment tools PACE and PC-CREAM 08," UKHSA, November 2022. Available at [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1118630/verification-and-validation-report-PACE-CREAM.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1118630/verification-and-validation-report-PACE-CREAM.pdf)
- 9-43 NEDC-34279P, "BWRX-300 UK GDA Analysis of Environmental Discharge Data for U.S. Nuclear Power Plants," Rev A, GE-Hitachi Nuclear Energy, Americas, LLC.
- 9-44 NRPB-W41, "Generalised habit data for radiological assessments," National Radiological Protection Board, 2003.
- 9-45 "CEFAS radiological habits survey data," Centre for Environment, Fisheries and Aquaculture Science. Available at [www.cefas.co.uk/expertise/surveys/habits/](http://www.cefas.co.uk/expertise/surveys/habits/) (Accessed June 2025).
- 9-46 "Use of Habits Data in Prospective Dose Assessments," NDAWG Guidance Note 7, Version 1.0 Final, 2013. Available at [https://www.ukhsa-protectionservices.org.uk/cms/assets/gfx/content/resource\\_4613cseeaebbf5.pdf](https://www.ukhsa-protectionservices.org.uk/cms/assets/gfx/content/resource_4613cseeaebbf5.pdf)
- 9-47 "Compendium of Dose Coefficients based on ICRP Publication 60," ICRP Publication 119. Ann. ICRP 41(Suppl.), 2012. Available at <https://www.icrp.org/publication.asp?id=ICRP%20Publication%20119>
- 9-48 "Doses to the Embryo and Fetus from Intakes of Radionuclides by the Mother," ICRP Publication 88. Ann. ICRP 31 (1-3), 2001. Available at <https://www.icrp.org/publication.asp?id=ICRP%20Publication%2088>
- 9-49 RCE-5, "Guidance on the Application of Dose Coefficients for the Embryo, Fetus and Breastfed Infant in Dose Assessments for Members of the Public (RCE-5)," Health Protection Agency, 2008. Available at [https://assets.publishing.service.gov.uk/media/5a7e4b9bed915d74e33f1506/RCE-5\\_dosecoef.pdf](https://assets.publishing.service.gov.uk/media/5a7e4b9bed915d74e33f1506/RCE-5_dosecoef.pdf)
- 9-50 IAEA-TECDOC-1616, "Quantification of Radionuclide Transfer in Terrestrial and Freshwater Environments for Radiological Assessments," IAEA, 2009. Available at [https://www-pub.iaea.org/MTCD/Publications/PDF/te\\_1616\\_web.pdf](https://www-pub.iaea.org/MTCD/Publications/PDF/te_1616_web.pdf)
- 9-51 "The Environmental Permitting (England and Wales) (Amendment) (No. 2) Regulations 2018," May 2018. Available at <https://www.legislation.gov.uk/uksi/2018/428/made>
- 9-52 "Short-term Releases to the Atmosphere technical methods and examples," NDAWG Guidance Note 6, June 2020. Available at [https://www.ukhsa-protectionservices.org.uk/cms/assets/gfx/content/resource\\_4623cs83eaa67227.pdf](https://www.ukhsa-protectionservices.org.uk/cms/assets/gfx/content/resource_4623cs83eaa67227.pdf)
- 9-53 NRPB-W54, "A methodology for Assessing Doses from Short-Term Planned Discharges to Atmosphere," J G Smith et al, National Radiological Protection Board, 2004.
- 9-54 "ADMS6," Cambridge Environmental Research Consultants. Available at <https://www.cerc.co.uk/environmental-software/ADMS-model.html> (Accessed June 2025).
- 9-55 DC\_PAK3.02, "Dose Coefficient File Package," K F Eckerman and R W Leggett, Oak Ridge National Laboratory. Available at <https://www.epa.gov/radiation/tools-calculating-radiation-dose-and-risk#tab> (Accessed June 2025).
- 9-56 "ERICA 2.0 (Environmental Risks from Ionising Contaminants: assessment and management)," ERICA. Available at <https://erica-tool.com/> (Accessed June 2025).

NEDO-34226 Revision C

- 9-57 “Environmental Protection – the Concept and Use of Reference Animals and Plants,” ICRP Publication 108. Ann. ICRP 38 (4-6)., ICRP, 2008. Available at <https://www.icrp.org/publication.asp?id=icrp%20publication%20108>
- 9-58 “Dose coefficients for nonhuman biota environmentally exposed to radiation,” ICRP Publication 136. Ann. ICRP 46(2)., ICRP, 2017. Available at <https://www.icrp.org/publication.asp?id=ICRP%20Publication%20136>
- 9-59 “ERICA Assessment Tool Help Documentation,” Version: 12, February 2016. Available at <https://erica-tool.com/wp-content/uploads/2020/09/help.pdf>
- 9-60 “Guidance on considering uncertainty and variability in radiological assessments,” NDAWG Guidance Note 4, 2011. Available at [https://www.ukhsa-protectionservices.org.uk/cms/assets/gfx/content/resource\\_4611cs14f2ebeab9.pdf](https://www.ukhsa-protectionservices.org.uk/cms/assets/gfx/content/resource_4611cs14f2ebeab9.pdf)

NEDO-34226 Revision C

**APPENDIX A      IRAT2 Outputs**

**Table A-1: Estimated Stage 1 Dose to the Representative Person  
 (Liquid Discharge, Bounding Case Scenario 2)**

| Radionuclide                       | External dose<br>μSv/y | Fish / shellfish<br>dose μSv/y | Total dose<br>μSv/y | % Contribution |
|------------------------------------|------------------------|--------------------------------|---------------------|----------------|
| Tritium                            | 0.0E+00                | 9.3E-03                        | 9.3E-03             | 0.2%           |
| Sodium-24                          | 1.0E-07                | 1.3E-07                        | 2.4E-07             | 0.0%           |
| <b>Phosphorus-32</b>               | <b>1.5E-08</b>         | <b>6.7E-01</b>                 | <b>6.7E-01</b>      | <b>12.2%</b>   |
| Chromium-51                        | 9.2E-04                | 2.9E-04                        | 1.2E-03             | 0.0%           |
| Manganese-54                       | 2.5E-01                | 2.9E-03                        | 2.5E-01             | 4.6%           |
| Iron-55                            | 0.0E+00                | 4.0E-04                        | 4.0E-04             | 0.0%           |
| Iron-59                            | 3.0E-02                | 4.7E-04                        | 3.0E-02             | 0.6%           |
| Cobalt-58                          | 3.3E-02                | 4.7E-03                        | 3.8E-02             | 0.7%           |
| <b>Cobalt-60</b>                   | <b>2.9E+00</b>         | <b>4.9E-02</b>                 | <b>3.0E+00</b>      | <b>54.0%</b>   |
| Nickel-63                          | 0.0E+00                | 4.2E-05                        | 4.2E-05             | 0.0%           |
| Copper-64                          | 1.1E-05                | 9.1E-03                        | 9.1E-03             | 0.2%           |
| <b>Zinc-65</b>                     | <b>4.2E-02</b>         | <b>9.0E-01</b>                 | <b>9.4E-01</b>      | <b>17.0%</b>   |
| Strontium-89                       | 1.7E-09                | 9.1E-06                        | 9.1E-06             | 0.0%           |
| Zirconium-95                       | 1.7E-02                | 6.3E-05                        | 1.7E-02             | 0.3%           |
| Niobium-95                         | 4.9E-03                | 2.2E-05                        | 4.9E-03             | 0.1%           |
| Molybdenum-99                      | 6.6E-06                | 7.5E-05                        | 8.2E-05             | 0.0%           |
| Technetium-99m                     | 1.8E-09                | 2.5E-06                        | 2.5E-06             | 0.0%           |
| Ruthenium-103                      | 4.3E-04                | 3.4E-05                        | 4.6E-04             | 0.0%           |
| Ruthenium-106                      | 3.3E-03                | 6.6E-04                        | 3.9E-03             | 0.1%           |
| Silver-110m                        | 1.9E-03                | 3.1E-02                        | 3.3E-02             | 0.6%           |
| Iodine-131                         | 1.1E-06                | 3.5E-04                        | 3.5E-04             | 0.0%           |
| Iodine-133                         | 7.3E-08                | 2.2E-05                        | 2.2E-05             | 0.0%           |
| Iodine-135                         | 1.1E-08                | 7.3E-07                        | 7.5E-07             | 0.0%           |
| Caesium-134                        | 4.1E-02                | 1.1E-02                        | 5.2E-02             | 0.9%           |
| Caesium-136                        | 5.0E-04                | 6.1E-04                        | 1.1E-03             | 0.0%           |
| Caesium-137                        | 7.3E-02                | 1.2E-02                        | 8.5E-02             | 1.5%           |
| Barium-140                         | 4.9E-03                | 2.1E-04                        | 5.1E-03             | 0.1%           |
| Cerium-141                         | 9.3E-05                | 4.9E-06                        | 9.8E-05             | 0.0%           |
| Cerium-144                         | 5.6E-04                | 2.8E-05                        | 5.9E-04             | 0.0%           |
| Other beta/gamma-emitting nuclides | 3.3E-01                | 5.2E-02                        | 3.8E-01             | 6.9%           |
| <b>Total μSv/y</b>                 | <b>3.8E+00</b>         | <b>1.8E+00</b>                 | <b>5.5E+00</b>      |                |

NEDO-34226 Revision C

**Table A-2: Estimated Stage 1 Dose to Wildlife  
 (Liquid Discharge, Bounding Case Scenario 2)**

| Radionuclide                                       | Dose rate $\mu\text{Gy/h}$ | % Contribution |
|--|----------------------------|----------------|
| Tritium  | 2.7E-05                    | 0.1%           |
| Sodium-24  | 3.5E-06                    | 0.0%           |
| Phosphorus-32                                      | 4.5E-04                    | 1.4%           |
| Chromium-51  | 1.3E-04                    | 0.4%           |
| <b>Manganese-54</b>                                | <b>3.4E-03</b>             | <b>10.9%</b>   |
| Iron-55  | 1.2E-06                    | 0.0%           |
| Iron-59  | 2.5E-03                    | 7.9%           |
| Cobalt-58  | 1.8E-03                    | 5.8%           |
| <b>Cobalt-60</b>                                   | <b>1.1E-02</b>             | <b>33.7%</b>   |
| Nickel-63  | 2.0E-07                    | 0.0%           |
| Copper-64  | 2.9E-04                    | 0.9%           |
| Zinc-65  | 7.5E-04                    | 2.4%           |
| Strontium-89                                       | 9.1E-08                    | 0.0%           |
| Zirconium-95                                       | 5.2E-04                    | 1.7%           |
| Niobium-95   | 5.1E-04                    | 1.6%           |
| Molybdenum-99                                      | 8.9E-05                    | 0.3%           |
| Technetium-99m                                     | 3.4E-06                    | 0.0%           |
| Ruthenium-103                                      | 4.1E-05                    | 0.1%           |
| Ruthenium-106                                      | 1.1E-04                    | 0.4%           |
| Silver-110m  | 3.9E-05                    | 0.1%           |
| Iodine-131   | 2.3E-05                    | 0.1%           |
| Iodine-133   | 1.5E-05                    | 0.1%           |
| Iodine-135   | 2.4E-06                    | 0.0%           |
| Caesium-134  | 2.8E-04                    | 0.9%           |
| Caesium-136  | 1.4E-04                    | 0.4%           |
| Caesium-137  | 1.7E-04                    | 0.5%           |
| <b>Barium-140</b>                                  | <b>8.6E-03</b>             | <b>27.6%</b>   |
| Cerium-141   | 1.5E-05                    | 0.1%           |
| Cerium-144   | 5.1E-05                    | 0.2%           |
| Other beta/gamma-emitting nuclides                 | 7.5E-04                    | 2.4%           |
| <b>Total dose rate <math>\mu\text{Gy/h}</math></b> | <b>3.1E-02</b>             |                |

NEDO-34226 Revision C

**Table A-3: Estimated Stage 1 Dose to the Representative Person  
 (Gaseous Discharge, Noble Gases Modelled as Xe-133)**

| Radionuclide     | Inhalation<br>Dose $\mu\text{Sv/y}$ | External dose<br>(cloud and<br>deposited)<br>$\mu\text{Sv/y}$ | Food<br>dose<br>$\mu\text{Sv/y}$ | Total<br>dose<br>$\mu\text{Sv/y}$ | %<br>Contribution |
|------------------|-------------------------------------|---|----------------------------------|-----------------------------------|-------------------|
| Tritium          | 6.9E-01                             | 0.0E+00   | 2.7E-01                          | 9.5E-01                           | 2.8%              |
| <b>Carbon-14</b> | <b>1.4E+01</b>                      | <b>2.6E-05</b>  | <b>1.4E+01</b>                   | <b>2.8E+01</b>                    | <b>83.2%</b>      |
| Sodium-24        | 8.5E-06                             | 2.8E-05   | 6.8E-08                          | 3.7E-05                           | 0.0%              |
| Phosphorus-32    | 1.0E-04                             | 2.0E-08   | 1.5E-04                          | 2.5E-04                           | 0.0%              |
| Argon-41         | 0.0E+00                             | 1.0E-03   | 0.0E+00                          | 1.0E-03                           | 0.0%              |
| Chromium-51      | 1.7E-05                             | 7.1E-05   | 1.6E-06                          | 8.9E-05                           | 0.0%              |
| Manganese-54     | 4.1E-04                             | 1.1E-02   | 3.4E-04                          | 1.2E-02                           | 0.0%              |
| Manganese-56     | 1.2E-06                             | 2.2E-06   | 0.0E+00                          | 3.5E-06                           | 0.0%              |
| Iron-55          | 1.8E-04                             | 6.5E-08   | 7.4E-04                          | 9.2E-04                           | 0.0%              |
| Iron-59          | 4.8E-04                             | 1.2E-03   | 4.8E-05                          | 1.7E-03                           | 0.0%              |
| Cobalt-58        | 1.9E-04                             | 1.4E-03   | 1.6E-05                          | 1.6E-03                           | 0.0%              |
| Cobalt-60        | 2.5E-03                             | 1.3E-01   | 5.5E-04                          | 1.3E-01                           | 0.4%              |
| Nickel-63        | 2.6E-07                             | 0.0E+00   | 1.1E-07                          | 3.7E-07                           | 0.0%              |
| Copper-64        | 1.8E-05                             | 2.8E-06   | 1.8E-07                          | 2.1E-05                           | 0.0%              |
| Zinc-65          | 1.8E-04                             | 2.5E-03   | 6.9E-04                          | 3.3E-03                           | 0.0%              |
| Krypton-85       | 0.0E+00                             | 2.8E-02   | 0.0E+00                          | 2.8E-02                           | 0.1%              |
| Krypton-85m      | 0.0E+00                             | 1.2E-02   | 0.0E+00                          | 1.2E-02                           | 0.0%              |
| Strontium-89     | 1.0E-05                             | 1.3E-09   | 1.8E-06                          | 1.2E-05                           | 0.0%              |
| Strontium-90     | 2.1E-06                             | 8.9E-12   | 4.9E-06                          | 7.0E-06                           | 0.0%              |
| Yttrium-90       | 4.2E-08                             | 1.7E-11   | 8.8E-10                          | 4.3E-08                           | 0.0%              |
| Zirconium-95     | 2.1E-04                             | 9.3E-04   | 2.2E-06                          | 1.1E-03                           | 0.0%              |
| Niobium-95       | 6.1E-05                             | 1.9E-04   | 1.1E-06                          | 2.6E-04                           | 0.0%              |
| Molybdenum-99    | 6.2E-05                             | 3.2E-06   | 4.0E-06                          | 6.9E-05                           | 0.0%              |
| Technetium-99m   | 9.4E-08                             | 8.7E-08   | 2.6E-09                          | 1.8E-07                           | 0.0%              |
| Ruthenium-103    | 2.4E-05                             | 3.4E-05   | 3.5E-07                          | 5.8E-05                           | 0.0%              |
| Ruthenium-106    | 4.6E-05                             | 1.9E-05   | 8.9E-07                          | 6.6E-05                           | 0.0%              |
| Silver-110m      | 4.1E-06                             | 6.0E-05   | 7.4E-06                          | 7.1E-05                           | 0.0%              |
| Iodine-131       | 1.8E-01                             | 2.0E-02   | 2.1E+00                          | 2.3E+00                           | 6.9%              |
| Iodine-132       | 6.0E-03                             | 4.0E-02   | 0.0E+00                          | 4.6E-02                           | 0.1%              |
| Iodine-133       | 2.1E-01                             | 1.8E-02   | 1.5E-01                          | 3.8E-01                           | 1.1%              |
| Iodine-134       | 8.0E-03                             | 8.0E-02   | 0.0E+00                          | 8.8E-02                           | 0.3%              |
| Iodine-135       | 3.0E-02                             | 9.6E-02   | 1.2E-03                          | 1.3E-01                           | 0.4%              |



NEDO-34226 Revision C

| Radionuclide                                  | Inhalation<br>Dose $\mu\text{Sv/y}$ | External dose<br>(cloud and<br>deposited)<br>$\mu\text{Sv/y}$ | Food<br>dose<br>$\mu\text{Sv/y}$ | Total<br>dose<br>$\mu\text{Sv/y}$ | %<br>Contribution |
|---|-------------------------------------|---|----------------------------------|-----------------------------------|-------------------|
| Xenon-133                                     | 0.0E+00                             | 1.5E+00   | 0.0E+00                          | 1.5E+00                           | 4.4%              |
| Caesium-134                                   | 9.8E-05                             | 2.4E-03   | 3.8E-04                          | 2.9E-03                           | 0.0%              |
| Caesium-136                                   | 1.0E-05                             | 4.3E-05   | 7.4E-06                          | 6.1E-05                           | 0.0%              |
| Caesium-137                                   | 1.0E-04                             | 6.6E-03   | 4.7E-04                          | 7.1E-03                           | 0.0%              |
| Barium-140                                    | 8.2E-04                             | 9.7E-04   | 1.5E-05                          | 1.8E-03                           | 0.0%              |
| Lanthanum-140                                 | 4.0E-05                             | 3.3E-05   | 4.7E-07                          | 7.3E-05                           | 0.0%              |
| Cerium-141                                    | 3.2E-05                             | 4.0E-06   | 3.6E-07                          | 3.7E-05                           | 0.0%              |
| Cerium-144                                    | 6.2E-05                             | 1.2E-06   | 2.1E-06                          | 6.5E-05                           | 0.0%              |
| Other beta/gamma-<br>emitting nuclides        | 8.0E-04                             | 5.0E-02   | 3.6E-03                          | 5.5E-02                           | 0.2%              |
| <b>Total dose <math>\mu\text{Sv/y}</math></b> | <b>1.6E+01</b>                      | <b>2.0E+00</b>  | <b>1.6E+01</b>                   | <b>3.4E+01</b>                    |                   |

NEDO-34226 Revision C

**Table A-4: Estimated Stage 1 Dose to the Representative Person  
 (Gaseous Discharge, Noble Gases Modelled as Kr-88)**

| Radionuclide      | Inhalation<br>Dose $\mu\text{Sv/y}$ | External dose<br>(cloud and<br>deposited)<br>$\mu\text{Sv/y}$ | Food<br>dose<br>$\mu\text{Sv/y}$ | Total<br>dose<br>$\mu\text{Sv/y}$ | %<br>Contribution |
|-------------------|-------------------------------------|---|----------------------------------|-----------------------------------|-------------------|
| Tritium           | 6.9E-01                             | 0.0E+00   | 2.7E-01                          | 9.5E-01                           | 0.7%              |
| <b>Carbon-14</b>  | <b>1.4E+01</b>                      | <b>2.6E-05</b>  | <b>1.4E+01</b>                   | <b>2.8E+01</b>                    | <b>21.8%</b>      |
| Sodium-24         | 8.5E-06                             | 2.8E-05   | 6.8E-08                          | 3.7E-05                           | 0.0%              |
| Phosphorus-32     | 1.0E-04                             | 2.0E-08   | 1.5E-04                          | 2.5E-04                           | 0.0%              |
| Argon-41          | 0.0E+00                             | 1.0E-03   | 0.0E+00                          | 1.0E-03                           | 0.0%              |
| Chromium-51       | 1.7E-05                             | 7.1E-05   | 1.6E-06                          | 8.9E-05                           | 0.0%              |
| Manganese-54      | 4.1E-04                             | 1.1E-02   | 3.4E-04                          | 1.2E-02                           | 0.0%              |
| Manganese-56      | 1.2E-06                             | 2.2E-06   | 0.0E+00                          | 3.5E-06                           | 0.0%              |
| Iron-55           | 1.8E-04                             | 6.5E-08   | 7.4E-04                          | 9.2E-04                           | 0.0%              |
| Iron-59           | 4.8E-04                             | 1.2E-03   | 4.8E-05                          | 1.7E-03                           | 0.0%              |
| Cobalt-58         | 1.9E-04                             | 1.4E-03   | 1.6E-05                          | 1.6E-03                           | 0.0%              |
| Cobalt-60         | 2.5E-03                             | 1.3E-01   | 5.5E-04                          | 1.3E-01                           | 0.1%              |
| Nickel-63         | 2.6E-07                             | 0.0E+00   | 1.1E-07                          | 3.7E-07                           | 0.0%              |
| Copper-64         | 1.8E-05                             | 2.8E-06   | 1.8E-07                          | 2.1E-05                           | 0.0%              |
| Zinc-65           | 1.8E-04                             | 2.5E-03   | 6.9E-04                          | 3.3E-03                           | 0.0%              |
| Krypton-85        | 0.0E+00                             | 2.8E-02   | 0.0E+00                          | 2.8E-02                           | 0.0%              |
| Krypton-85m       | 0.0E+00                             | 1.3E-02   | 0.0E+00                          | 1.3E-02                           | 0.0%              |
| <b>Krypton-88</b> | <b>0.0E+00</b>                      | <b>9.6E+01</b>  | <b>0.0E+00</b>                   | <b>9.6E+01</b>                    | <b>74.9%</b>      |
| Strontium-89      | 1.0E-05                             | 1.3E-09   | 1.8E-06                          | 1.2E-05                           | 0.0%              |
| Strontium-90      | 2.1E-06                             | 8.9E-12   | 4.9E-06                          | 7.0E-06                           | 0.0%              |
| Yttrium-90        | 4.2E-08                             | 1.7E-11   | 8.8E-10                          | 4.3E-08                           | 0.0%              |
| Zirconium-95      | 2.1E-04                             | 9.3E-04   | 2.2E-06                          | 1.1E-03                           | 0.0%              |
| Niobium-95        | 6.1E-05                             | 1.9E-04   | 1.1E-06                          | 2.6E-04                           | 0.0%              |
| Molybdenum-99     | 6.2E-05                             | 3.2E-06   | 4.0E-06                          | 6.9E-05                           | 0.0%              |
| Technetium-99m    | 9.4E-08                             | 8.7E-08   | 2.6E-09                          | 1.8E-07                           | 0.0%              |
| Ruthenium-103     | 2.4E-05                             | 3.4E-05   | 3.5E-07                          | 5.8E-05                           | 0.0%              |
| Ruthenium-106     | 4.6E-05                             | 1.9E-05   | 8.9E-07                          | 6.6E-05                           | 0.0%              |
| Silver-110m       | 4.1E-06                             | 6.0E-05   | 7.4E-06                          | 7.1E-05                           | 0.0%              |
| Iodine-131        | 1.8E-01                             | 2.0E-02   | 2.1E+00                          | 2.3E+00                           | 1.8%              |
| Iodine-132        | 6.0E-03                             | 4.0E-02   | 0.0E+00                          | 4.6E-02                           | 0.0%              |
| Iodine-133        | 2.1E-01                             | 1.8E-02   | 1.5E-01                          | 3.8E-01                           | 0.3%              |
| Iodine-134        | 8.0E-03                             | 8.0E-02   | 0.0E+00                          | 8.8E-02                           | 0.1%              |

NEDO-34226 Revision C

| Radionuclide                                  | Inhalation<br>Dose $\mu\text{Sv/y}$ | External dose<br>(cloud and<br>deposited)<br>$\mu\text{Sv/y}$ | Food<br>dose<br>$\mu\text{Sv/y}$ | Total<br>dose<br>$\mu\text{Sv/y}$ | %<br>Contribution |
|---|-------------------------------------|---|----------------------------------|-----------------------------------|-------------------|
| Iodine-135                                    | 3.0E-02                             | 9.6E-02   | 1.2E-03                          | 1.3E-01                           | 0.1%              |
| Xenon-133                                     | 0.0E+00                             | 1.1E-01   | 0.0E+00                          | 1.1E-01                           | 0.1%              |
| Caesium-134                                   | 9.8E-05                             | 2.4E-03   | 3.8E-04                          | 2.9E-03                           | 0.0%              |
| Caesium-136                                   | 1.0E-05                             | 4.3E-05   | 7.4E-06                          | 6.1E-05                           | 0.0%              |
| Caesium-137                                   | 1.0E-04                             | 6.6E-03   | 4.7E-04                          | 7.1E-03                           | 0.0%              |
| Barium-140                                    | 8.2E-04                             | 9.7E-04   | 1.5E-05                          | 1.8E-03                           | 0.0%              |
| Lanthanum-140                                 | 4.0E-05                             | 3.3E-05   | 4.7E-07                          | 7.3E-05                           | 0.0%              |
| Cerium-141                                    | 3.2E-05                             | 4.0E-06   | 3.6E-07                          | 3.7E-05                           | 0.0%              |
| Cerium-144                                    | 6.2E-05                             | 1.2E-06   | 2.1E-06                          | 6.5E-05                           | 0.0%              |
| Other beta/gamma-<br>emitting nuclides        | 8.0E-04                             | 5.0E-02   | 3.6E-03                          | 5.5E-02                           | 0.0%              |
| <b>Total dose <math>\mu\text{Sv/y}</math></b> | <b>1.6E+01</b>                      | <b>9.7E+01</b>  | <b>1.6E+01</b>                   | <b>1.3E+02</b>                    |                   |

NEDO-34226 Revision C

**Table A-5: Estimated Stage 1 Dose to Wildlife  
 (Gaseous Discharge, Noble Gases Modelled as Xe-133)**

| Radionuclide     | Dose rate $\mu\text{Gy/h}$ | % Contribution |
|------------------|----------------------------|----------------|
| Tritium          | 3.4E-03                    | 6.8%           |
| <b>Carbon-14</b> | <b>4.5E-02</b>             | 90.1%          |
| Sodium-24        | 3.8E-09                    | 0.0%           |
| Phosphorus-32    | 1.0E-06                    | 0.0%           |
| Argon-41         | 5.8E-07                    | 0.0%           |
| Chromium-51      | 7.6E-09                    | 0.0%           |
| Manganese-54     | 1.6E-06                    | 0.0%           |
| Manganese-56     | 7.2E-11                    | 0.0%           |
| Iron-55          | 7.3E-07                    | 0.0%           |
| Iron-59          | 1.5E-07                    | 0.0%           |
| Cobalt-58        | 1.9E-07                    | 0.0%           |
| Cobalt-60        | 2.2E-05                    | 0.0%           |
| Nickel-63        | 6.7E-10                    | 0.0%           |
| Coppr-64         | 1.1E-09                    | 0.0%           |
| Zinc-65          | 7.9E-07                    | 0.0%           |
| Krypton-85       | 1.2E-04                    | 0.2%           |
| Krypton-85m      | 1.9E-06                    | 0.0%           |
| Strontium-89     | 3.5E-09                    | 0.0%           |
| Strontium-90     | 2.7E-08                    | 0.0%           |
| Yttrium-90       | 1.3E-13                    | 0.0%           |
| Zirconium-95     | 4.7E-08                    | 0.0%           |
| Niobium-95       | 2.4E-08                    | 0.0%           |
| Molybdenum-99    | 8.9E-10                    | 0.0%           |
| Technetium-99m   | 9.2E-12                    | 0.0%           |
| Ruthenium-103    | 8.6E-09                    | 0.0%           |
| Ruthenium-106    | 4.0E-08                    | 0.0%           |
| Silver-110m      | 9.2E-09                    | 0.0%           |
| Iodine-131       | 7.3E-06                    | 0.0%           |
| Iodine-132       | 2.8E-06                    | 0.0%           |
| Iodine-133       | 6.2E-06                    | 0.0%           |
| Iodine-134       | 3.4E-06                    | 0.0%           |
| Iodine-135       | 8.4E-06                    | 0.0%           |
| Xenon-133        | 1.3E-03                    | 2.6%           |
| Caesium-134      | 1.0E-06                    | 0.0%           |

NEDO-34226 Revision C

| Radionuclide                                       | Dose rate $\mu\text{Gy/h}$ | % Contribution |
|--|----------------------------|----------------|
| Caesium-136  | 1.2E-08                    | 0.0%           |
| Caesium-137  | 6.4E-06                    | 0.0%           |
| Barium-140   | 7.3E-07                    | 0.0%           |
| Lanthanum-140                                      | 2.9E-09                    | 0.0%           |
| Cerium-141   | 3.6E-10                    | 0.0%           |
| Cerium-144   | 1.2E-09                    | 0.0%           |
| Other beta/gamma-emitting nuclides                 | 4.9E-05                    | 0.1%           |
| <b>Total dose rate <math>\mu\text{Gy/h}</math></b> | <b>5.0E-02</b>             |                |

NEDO-34226 Revision C

**Table A-6: Estimated Stage 2 Dose to the Representative Person  
(Liquid Discharge, Bounding Case Scenario 2)**

| Radionuclide         | External dose<br>μSv/y | Fish / shellfish dose<br>μSv/y | Total dose<br>μSv/y | %<br>Contribution |
|----------------------|------------------------|--------------------------------|---------------------|-------------------|
| Tritium              | 0.0E+00                | 1.2E-03                        | 1.2E-03             | 0.2%              |
| Sodium-24            | 1.3E-08                | 1.7E-08                        | 3.1E-08             | 0.0%              |
| <b>Phosphorus-32</b> | <b>1.9E-09</b>         | <b>8.7E-02</b>                 | <b>8.7E-02</b>      | <b>12.4%</b>      |
| Chromium-51          | 1.2E-04                | 3.7E-05                        | 1.6E-04             | 0.0%              |
| Manganese-52         | 6.3E-04                | 2.1E-04                        | 8.4E-04             | 0.1%              |
| Manganese-54         | 3.3E-02                | 3.8E-04                        | 3.3E-02             | 4.7%              |
| Iron-55              | 0.0E+00                | 5.1E-05                        | 5.1E-05             | 0.0%              |
| Iron-59              | 3.9E-03                | 6.1E-05                        | 4.0E-03             | 0.6%              |
| Cobalt-58            | 4.3E-03                | 6.1E-04                        | 4.9E-03             | 0.7%              |
| <b>Cobalt-60</b>     | <b>3.8E-01</b>         | <b>6.3E-03</b>                 | <b>3.9E-01</b>      | <b>54.8%</b>      |
| Nickel-63            | 0.0E+00                | 5.5E-06                        | 5.5E-06             | 0.0%              |
| Copper-64            | 1.4E-06                | 1.2E-03                        | 1.2E-03             | 0.2%              |
| <b>Zinc-65</b>       | <b>5.4E-03</b>         | <b>1.2E-01</b>                 | <b>1.2E-01</b>      | <b>17.3%</b>      |
| Strontium-89         | 2.2E-10                | 1.2E-06                        | 1.2E-06             | 0.0%              |
| Zirconium-95         | 2.2E-03                | 8.2E-06                        | 2.2E-03             | 0.3%              |
| Niobium-95           | 6.3E-04                | 2.8E-06                        | 6.3E-04             | 0.1%              |
| Molybdenum-99        | 8.5E-07                | 9.8E-06                        | 1.1E-05             | 0.0%              |
| Technetium-99m       | 2.4E-10                | 3.2E-07                        | 3.2E-07             | 0.0%              |
| Ruthenium-103        | 5.5E-05                | 4.4E-06                        | 6.0E-05             | 0.0%              |
| Ruthenium-106        | 4.2E-04                | 8.6E-05                        | 5.1E-04             | 0.1%              |
| Silver-110m          | 2.4E-04                | 4.1E-03                        | 4.3E-03             | 0.6%              |
| Iodine-131           | 1.5E-07                | 4.5E-05                        | 4.5E-05             | 0.0%              |
| Iodine-133           | 9.5E-09                | 2.9E-06                        | 2.9E-06             | 0.0%              |
| Iodine-135           | 1.4E-09                | 9.5E-08                        | 9.7E-08             | 0.0%              |
| Caesium-134          | 5.4E-03                | 1.4E-03                        | 6.8E-03             | 1.0%              |
| Caesium-136          | 6.5E-05                | 8.0E-05                        | 1.5E-04             | 0.0%              |
| Caesium-137          | 3.2E-02                | 5.2E-03                        | 3.8E-02             | 5.3%              |
| Barium-140           | 6.4E-04                | 2.8E-05                        | 6.6E-04             | 0.1%              |
| Cerium-141           | 1.2E-05                | 6.4E-07                        | 1.3E-05             | 0.0%              |
| Cerium-144           | 7.3E-05                | 3.6E-06                        | 7.6E-05             | 0.0%              |
| Lead-212             | 1.4E-06                | 1.2E-02                        | 1.2E-02             | 1.7%              |
| <b>Total μSv/y</b>   | <b>4.7E-01</b>         | <b>2.4E-01</b>                 | <b>7.1E-01</b>      |                   |

NEDO-34226 Revision C

**Table A-7: Estimated Stage 2 Dose to Wildlife  
(Liquid Discharge, Bounding Case Scenario 2)**

| Radionuclide                                       | Dose rate $\mu\text{Gy/h}$ | % Contribution |
|--|----------------------------|----------------|
| Tritium  | 3.5E-06                    | 0.0%           |
| Sodium-24  | 4.5E-07                    | 0.0%           |
| Phosphorus-32                                      | 5.8E-05                    | 0.1%           |
| Chromium-51  | 1.7E-05                    | 0.0%           |
| Manganese-52                                       | 4.0E-04                    | 0.9%           |
| Manganese-54                                       | 4.4E-04                    | 0.9%           |
| Iron-55  | 1.6E-07                    | 0.0%           |
| Iron-59  | 3.2E-04                    | 0.7%           |
| Cobalt-58  | 2.4E-04                    | 0.5%           |
| Cobalt-60  | 1.4E-03                    | 2.9%           |
| Nickel-63  | 2.6E-08                    | 0.0%           |
| Copper-64  | 3.8E-05                    | 0.1%           |
| Zinc-65  | 9.7E-05                    | 0.2%           |
| Strontium-89                                       | 1.2E-08                    | 0.0%           |
| Zirconium-95                                       | 6.7E-05                    | 0.1%           |
| Niobium-95   | 6.6E-05                    | 0.1%           |
| Molybdenum-99                                      | 1.2E-05                    | 0.0%           |
| Technetium-99m                                     | 4.5E-07                    | 0.0%           |
| Ruthenium-103                                      | 5.3E-06                    | 0.0%           |
| Ruthenium-106                                      | 1.5E-05                    | 0.0%           |
| Silver-110m  | 5.0E-06                    | 0.0%           |
| Iodine-131   | 2.9E-06                    | 0.0%           |
| Iodine-133   | 2.0E-06                    | 0.0%           |
| Iodine-135   | 3.1E-07                    | 0.0%           |
| Caesium-134  | 3.6E-05                    | 0.1%           |
| Caesium-136  | 1.8E-05                    | 0.0%           |
| Caesium-137  | 7.4E-05                    | 0.2%           |
| Barium-140   | 1.1E-03                    | 2.4%           |
| Cerium-141   | 1.9E-06                    | 0.0%           |
| Cerium-144   | 6.6E-06                    | 0.0%           |
| <b>Lead-212</b>                                    | <b>4.3E-02</b>             | <b>90.7%</b>   |
| <b>Total dose rate <math>\mu\text{Gy/h}</math></b> | <b>4.7E-02</b>             |                |

NEDO-34226 Revision C

**Table A-8: Estimated Stage 2 Dose to the Representative Person  
(Gaseous Discharge, Noble Gases Modelled as Xe-133)**

| Radionuclide      | Inhalation Dose $\mu\text{Sv/y}$ | External dose (cloud and deposited) $\mu\text{Sv/y}$ | Food dose $\mu\text{Sv/y}$ | Total dose $\mu\text{Sv/y}$ | % Contribution |
|-------------------|----------------------------------|--|----------------------------|-----------------------------|----------------|
| Tritium           | 4.8E-02                          | 0.0E+00  | 1.7E-01                    | 2.2E-01                     | 1.9%           |
| <b>Carbon-14</b>  | <b>1.0E+00</b>                   | <b>1.8E-06</b>                                       | <b>8.7E+00</b>             | <b>9.7E+00</b>              | <b>84.0%</b>   |
| Sodium-24         | 6.0E-07                          | 2.0E-06  | 4.4E-08                    | 2.6E-06                     | 0.0%           |
| Phosphorus-32     | 7.1E-06                          | 1.4E-09  | 9.6E-05                    | 1.0E-04                     | 0.0%           |
| Argon-41          | 0.0E+00                          | 7.3E-05  | 0.0E+00                    | 7.3E-05                     | 0.0%           |
| Chromium-51       | 1.2E-06                          | 5.0E-06  | 1.0E-06                    | 7.1E-06                     | 0.0%           |
| Manganese-52      | 4.0E-06                          | 1.1E-05  | 4.0E-06                    | 1.9E-05                     | 0.0%           |
| Manganese-54      | 2.8E-05                          | 7.7E-04  | 2.2E-04                    | 1.0E-03                     | 0.0%           |
| Manganese-56      | 8.5E-08                          | 1.6E-07  | 0.0E+00                    | 2.4E-07                     | 0.0%           |
| Iron-55           | 1.3E-05                          | 4.5E-09  | 4.7E-04                    | 4.9E-04                     | 0.0%           |
| Iron-59           | 3.4E-05                          | 8.3E-05  | 3.1E-05                    | 1.5E-04                     | 0.0%           |
| Cobalt-58         | 1.3E-05                          | 9.8E-05  | 1.0E-05                    | 1.2E-04                     | 0.0%           |
| Cobalt-60         | 1.7E-04                          | 8.8E-03  | 3.5E-04                    | 9.3E-03                     | 0.1%           |
| Nickel-63         | 1.8E-08                          | 0.0E+00  | 7.2E-08                    | 8.9E-08                     | 0.0%           |
| Copper-64         | 1.3E-06                          | 1.9E-07  | 1.1E-07                    | 1.6E-06                     | 0.0%           |
| Zinc-65           | 1.2E-05                          | 1.7E-04  | 4.4E-04                    | 6.3E-04                     | 0.0%           |
| Krypton-85        | 0.0E+00                          | 2.0E-03  | 0.0E+00                    | 2.0E-03                     | 0.0%           |
| Krypton-85m       | 0.0E+00                          | 8.7E-04  | 0.0E+00                    | 8.7E-04                     | 0.0%           |
| Strontium-89      | 7.3E-07                          | 9.2E-11  | 1.1E-06                    | 1.9E-06                     | 0.0%           |
| Strontium-90      | 1.5E-07                          | 6.2E-13  | 3.1E-06                    | 3.3E-06                     | 0.0%           |
| Yttrium-90        | 2.9E-09                          | 1.2E-12  | 5.7E-10                    | 3.5E-09                     | 0.0%           |
| Zirconium-95      | 1.4E-05                          | 6.5E-05  | 1.4E-06                    | 8.1E-05                     | 0.0%           |
| Niobium-95        | 4.3E-06                          | 1.4E-05  | 7.0E-07                    | 1.9E-05                     | 0.0%           |
| Molybdenum-99     | 4.3E-06                          | 2.2E-07  | 2.6E-06                    | 7.1E-06                     | 0.0%           |
| Technetium-99m    | 6.6E-09                          | 6.1E-09  | 1.7E-09                    | 1.4E-08                     | 0.0%           |
| Ruthenium-103     | 1.7E-06                          | 2.4E-06  | 2.3E-07                    | 4.3E-06                     | 0.0%           |
| Ruthenium-106     | 3.2E-06                          | 1.3E-06  | 5.7E-07                    | 5.1E-06                     | 0.0%           |
| Silver-110m       | 2.9E-07                          | 4.2E-06  | 4.7E-06                    | 9.2E-06                     | 0.0%           |
| <b>Iodine-131</b> | <b>1.3E-02</b>                   | <b>1.4E-03</b>                                       | <b>1.3E+00</b>             | <b>1.4E+00</b>              | <b>11.9%</b>   |
| Iodine-132        | 4.2E-04                          | 2.8E-03  | 0.0E+00                    | 3.2E-03                     | 0.0%           |
| Iodine-133        | 1.5E-02                          | 1.3E-03  | 9.7E-02                    | 1.1E-01                     | 1.0%           |
| Iodine-134        | 5.6E-04                          | 5.6E-03  | 0.0E+00                    | 6.2E-03                     | 0.1%           |
| Iodine-135        | 2.1E-03                          | 6.7E-03  | 7.4E-04                    | 9.6E-03                     | 0.1%           |



NEDO-34226 Revision C

| Radionuclide                                      | Inhalation<br>Dose<br>$\mu\text{Sv/y}$ | External dose<br>(cloud and<br>deposited) $\mu\text{Sv/y}$ | Food<br>dose<br>$\mu\text{Sv/y}$ | Total<br>dose<br>$\mu\text{Sv/y}$ | %<br>Contribution |
|---|--|--|----------------------------------|-----------------------------------|-------------------|
| Xenon-133   | 0.0E+00                                | 1.0E-01  | 0.0E+00                          | 1.0E-01                           | 0.9%              |
| Caesium-134                                       | 6.9E-06                                | 1.7E-04  | 2.5E-04                          | 4.2E-04                           | 0.0%              |
| Caesium-136                                       | 7.0E-07                                | 3.0E-06  | 4.7E-06                          | 8.4E-06                           | 0.0%              |
| Caesium-137                                       | 4.6E-05                                | 2.9E-03  | 1.9E-03                          | 4.9E-03                           | 0.0%              |
| Barium-140  | 5.7E-05                                | 6.8E-05  | 9.4E-06                          | 1.3E-04                           | 0.0%              |
| Lanthanum-140                                     | 2.8E-06                                | 2.3E-06  | 3.0E-07                          | 5.4E-06                           | 0.0%              |
| Cerium-141  | 2.3E-06                                | 2.8E-07  | 2.3E-07                          | 2.8E-06                           | 0.0%              |
| Cerium-144  | 4.4E-06                                | 8.2E-08  | 1.3E-06                          | 5.8E-06                           | 0.0%              |
| Lead-212  | 1.4E-04                                | 3.5E-08  | 9.4E-08                          | 1.4E-04                           | 0.0%              |
| <b>Total dose<br/><math>\mu\text{Sv/y}</math></b> | <b>1.1E+00</b>                         | <b>1.4E-01</b>   | <b>1.0E+01</b>                   | <b>1.1E+01</b>                    |                   |

NEDO-34226 Revision C

**Table A-9: Estimated Stage 2 Dose to the Representative Person  
(Gaseous Discharge, Noble Gases Modelled as Kr-88)**

| Radionuclide      | Inhalation Dose $\mu\text{Sv/y}$ | External dose (cloud and deposited) $\mu\text{Sv/y}$ | Food dose $\mu\text{Sv/y}$ | Total dose $\mu\text{Sv/y}$ | % Contribution |
|-------------------|----------------------------------|--|----------------------------|-----------------------------|----------------|
| Tritium           | 4.8E-02                          | 0.0E+00  | 1.7E-01                    | 2.2E-01                     | 1.2%           |
| <b>Carbon-14</b>  | <b>1.0E+00</b>                   | <b>1.8E-06</b>                                       | <b>8.7E+00</b>             | <b>9.7E+00</b>              | <b>53.1%</b>   |
| Sodium-24         | 6.0E-07                          | 2.0E-06  | 4.4E-08                    | 2.6E-06                     | 0.0%           |
| Phosphorus-32     | 7.1E-06                          | 1.4E-09  | 9.6E-05                    | 1.0E-04                     | 0.0%           |
| Argon-41          | 0.0E+00                          | 7.3E-05  | 0.0E+00                    | 7.3E-05                     | 0.0%           |
| Chromium-51       | 1.2E-06                          | 5.0E-06  | 1.0E-06                    | 7.1E-06                     | 0.0%           |
| Manganese-52      | 4.0E-06                          | 1.1E-05  | 4.0E-06                    | 1.9E-05                     | 0.0%           |
| Manganese-54      | 2.8E-05                          | 7.7E-04  | 2.2E-04                    | 1.0E-03                     | 0.0%           |
| Manganese-56      | 8.5E-08                          | 1.6E-07  | 0.0E+00                    | 2.4E-07                     | 0.0%           |
| Iron-55           | 1.3E-05                          | 4.5E-09  | 4.7E-04                    | 4.9E-04                     | 0.0%           |
| Iron-59           | 3.4E-05                          | 8.3E-05  | 3.1E-05                    | 1.5E-04                     | 0.0%           |
| Cobalt-58         | 1.3E-05                          | 9.8E-05  | 1.0E-05                    | 1.2E-04                     | 0.0%           |
| Cobalt-60         | 1.7E-04                          | 8.8E-03  | 3.5E-04                    | 9.3E-03                     | 0.1%           |
| Nickel-63         | 1.8E-08                          | 0.0E+00  | 7.2E-08                    | 8.9E-08                     | 0.0%           |
| Copper-64         | 1.3E-06                          | 1.9E-07  | 1.1E-07                    | 1.6E-06                     | 0.0%           |
| Zinc-65           | 1.2E-05                          | 1.7E-04  | 4.4E-04                    | 6.3E-04                     | 0.0%           |
| Krypton-85        | 0.0E+00                          | 2.0E-03  | 0.0E+00                    | 2.0E-03                     | 0.0%           |
| Krypton-85m       | 0.0E+00                          | 8.7E-04  | 0.0E+00                    | 8.7E-04                     | 0.0%           |
| <b>Krypton-88</b> | <b>0.0E+00</b>                   | <b>6.7E+00</b>                                       | <b>0.0E+00</b>             | <b>6.7E+00</b>              | <b>36.9%</b>   |
| Strontium-89      | 7.3E-07                          | 9.2E-11  | 1.1E-06                    | 1.9E-06                     | 0.0%           |
| Strontium-90      | 1.5E-07                          | 6.2E-13  | 3.1E-06                    | 3.3E-06                     | 0.0%           |
| Yttrium-90        | 2.9E-09                          | 1.2E-12  | 5.7E-10                    | 3.5E-09                     | 0.0%           |
| Zirconium-95      | 1.4E-05                          | 6.5E-05  | 1.4E-06                    | 8.1E-05                     | 0.0%           |
| Niobium-95        | 4.3E-06                          | 1.4E-05  | 7.0E-07                    | 1.9E-05                     | 0.0%           |
| Molybdenum-99     | 4.3E-06                          | 2.2E-07  | 2.6E-06                    | 7.1E-06                     | 0.0%           |
| Technetium-99m    | 6.6E-09                          | 6.1E-09  | 1.7E-09                    | 1.4E-08                     | 0.0%           |
| Ruthenium-103     | 1.7E-06                          | 2.4E-06  | 2.3E-07                    | 4.3E-06                     | 0.0%           |
| Ruthenium-106     | 3.2E-06                          | 1.3E-06  | 5.7E-07                    | 5.1E-06                     | 0.0%           |
| Silver-110m       | 2.9E-07                          | 4.2E-06  | 4.7E-06                    | 9.2E-06                     | 0.0%           |
| <b>Iodine-131</b> | <b>1.3E-02</b>                   | <b>1.4E-03</b>                                       | <b>1.3E+00</b>             | <b>1.4E+00</b>              | <b>7.5%</b>    |
| Iodine-132        | 4.2E-04                          | 2.8E-03  | 0.0E+00                    | 3.2E-03                     | 0.0%           |
| Iodine-133        | 1.5E-02                          | 1.3E-03  | 9.7E-02                    | 1.1E-01                     | 0.6%           |
| Iodine-134        | 5.6E-04                          | 5.6E-03  | 0.0E+00                    | 6.2E-03                     | 0.0%           |

NEDO-34226 Revision C

| Radionuclide                                      | Inhalation<br>Dose<br>$\mu\text{Sv/y}$ | External dose<br>(cloud and<br>deposited) $\mu\text{Sv/y}$ | Food<br>dose<br>$\mu\text{Sv/y}$ | Total<br>dose<br>$\mu\text{Sv/y}$ | %<br>Contribution |
|---|--|--|----------------------------------|-----------------------------------|-------------------|
| Iodine-135  | 2.1E-03                                | 6.7E-03  | 7.4E-04                          | 9.6E-03                           | 0.1%              |
| Xenon-133   | 0.0E+00                                | 8.0E-03  | 0.0E+00                          | 8.0E-03                           | 0.0%              |
| Caesium-134                                       | 6.9E-06                                | 1.7E-04  | 2.5E-04                          | 4.2E-04                           | 0.0%              |
| Caesium-136                                       | 7.0E-07                                | 3.0E-06  | 4.7E-06                          | 8.4E-06                           | 0.0%              |
| Caesium-137                                       | 4.6E-05                                | 2.9E-03  | 1.9E-03                          | 4.9E-03                           | 0.0%              |
| Barium-140  | 5.7E-05                                | 6.8E-05  | 9.4E-06                          | 1.3E-04                           | 0.0%              |
| Lanthanum-140                                     | 2.8E-06                                | 2.3E-06  | 3.0E-07                          | 5.4E-06                           | 0.0%              |
| Cerium-141  | 2.3E-06                                | 2.8E-07  | 2.3E-07                          | 2.8E-06                           | 0.0%              |
| Cerium-144  | 4.4E-06                                | 8.2E-08  | 1.3E-06                          | 5.8E-06                           | 0.0%              |
| Pb-212  | 1.4E-04                                | 3.5E-08  | 9.4E-08                          | 1.4E-04                           | 0.0%              |
| <b>Total dose<br/><math>\mu\text{Sv/y}</math></b> | <b>1.1E+00</b>                         | <b>6.8E+00</b>   | <b>1.0E+01</b>                   | <b>1.8E+01</b>                    |                   |

NEDO-34226 Revision C

**Table A-10: Estimated Stage 2 Dose to Wildlife  
 (Gaseous Discharge, Noble Gases Modelled as Xe-133)**

| Radionuclide     | Dose rate $\mu\text{Gy/h}$ | % Contribution |
|------------------|----------------------------|----------------|
| Tritium          | 2.2E-03                    | 6.8%           |
| <b>Carbon-14</b> | <b>2.9E-02</b>             | <b>90.1%</b>   |
| Sodium-24        | 2.5E-09                    | 0.0%           |
| Phosphorus-32    | 6.6E-07                    | 0.0%           |
| Argon-41         | 3.7E-07                    | 0.0%           |
| Chromium-51      | 4.9E-09                    | 0.0%           |
| Manganese-52     | 9.5E-09                    | 0.0%           |
| Manganese-54     | 1.1E-06                    | 0.0%           |
| Manganese-56     | 4.6E-11                    | 0.0%           |
| Iron-55          | 4.6E-07                    | 0.0%           |
| Iron-59          | 9.6E-08                    | 0.0%           |
| Cobalt-58        | 1.2E-07                    | 0.0%           |
| Cobalt-60        | 1.4E-05                    | 0.0%           |
| Nickel-63        | 4.3E-10                    | 0.0%           |
| Coppr-64         | 6.9E-10                    | 0.0%           |
| Zinc-65          | 5.0E-07                    | 0.0%           |
| Krypton-85       | 7.7E-05                    | 0.2%           |
| Krypton-85m      | 1.2E-06                    | 0.0%           |
| Strontium-89     | 2.2E-09                    | 0.0%           |
| Strontium-90     | 1.8E-08                    | 0.0%           |
| Yttrium-90       | 8.2E-14                    | 0.0%           |
| Zirconium-95     | 3.0E-08                    | 0.0%           |
| Niobium-95       | 1.5E-08                    | 0.0%           |
| Molybdenum-99    | 5.7E-10                    | 0.0%           |
| Technetium-99m   | 5.9E-12                    | 0.0%           |
| Ruthenium-103    | 5.5E-09                    | 0.0%           |
| Ruthenium-106    | 2.6E-08                    | 0.0%           |
| Silver-110m      | 5.9E-09                    | 0.0%           |
| Iodine-131       | 4.7E-06                    | 0.0%           |
| Iodine-132       | 1.8E-06                    | 0.0%           |
| Iodine-133       | 3.9E-06                    | 0.0%           |
| Iodine-134       | 2.2E-06                    | 0.0%           |
| Iodine-135       | 5.4E-06                    | 0.0%           |
| Xenon-133        | 8.3E-04                    | 2.6%           |

NEDO-34226 Revision C

| Radionuclide                                       | Dose rate $\mu\text{Gy/h}$ | % Contribution |
|--|----------------------------|----------------|
| Caesium-134  | 6.4E-07                    | 0.0%           |
| Caesium-136  | 7.8E-09                    | 0.0%           |
| Caesium-137  | 2.6E-05                    | 0.1%           |
| Barium-140   | 4.7E-07                    | 0.0%           |
| Lanthanum-140                                      | 1.9E-09                    | 0.0%           |
| Cerium-141   | 2.3E-10                    | 0.0%           |
| Cerium-144   | 7.6E-10                    | 0.0%           |
| Lead-212   | 1.6E-08                    | 0.0%           |
| <b>Total dose rate <math>\mu\text{Gy/h}</math></b> | <b>3.2E-02</b>             |                |

NEDO-34226 Revision C

## APPENDIX B Forward Action Plan

The following actions have been identified for incorporation into the Forward Action Plan for development of a UK version of the BWRX-300 SMR:

**Table B-1: Forward Action Plan**

| Action ID | Finding   | Forward Action   | Delivery Phase |
|-----------|---|--|----------------|
| PER9-118  | A more detailed dose assessment is required.  | Dose assessment to be refined for future design development, licensing, and permitting stages.<br><br>PC-CREAM 08 offers more comprehensive assessment of prospective individual and collective doses for routine continuous discharges of liquid and gaseous radioactive effluents. This can be performed using generic data.<br><br>The dose assessment can be further refined using site - specific data when a site has been identified. | For PCSR/PCER  |
| PER9-119  | The IRAT2 tool used for Step 1 and Step 2 considers the following exposure pathways:<br><br>Liquid discharges: external radiation from radionuclides deposited in shore sediments & consumption of seafood incorporating radionuclides.<br><br>Gaseous discharges: Inhalation of radionuclides in the effluent plume, external radiation from radionuclides in the effluent plume and deposited to the ground, consumption of terrestrial food incorporating radionuclides deposited to the ground. | Review and expansion of potential exposure pathways.   | For PCSR/PCER  |

NEDO-34226 Revision C

| Action ID | Finding   | Forward Action   | Delivery Phase  |
|-----------|---|--|---|
| PER9-120  | Direct radiation dose has been based on a review of OPEX from U.S. operational BWR plants.                    | The direct dose rates should be assessed for the BWRX-300 based on mathematical modelling of buildings containing a source term.<br><br>A review should be made of public occupancy rates, and these occupancies then used alongside the modelled dose rates to make a more realistic estimate of the direct radiation dose.   | For PCSR/PCER   |
| PER9-121  | The dose due to a short-term release has not been assessed during Step 1 or Step 2.                           | The short-term release scenario proposed at GDA Step 2 is a fuel pin failure, leading to a release over 24 hours. Potential additional short-term release scenarios will be reviewed and confirmed during the more detailed dose assessment, when the associated source term information is available.<br><br>Exposure pathways and habits data will be identified, dispersion modelled, and the dose assessed for the short-term release scenario(s) using methodology detailed in National Dose Assessment Working Group (NDAWG) Guidance Note 6B. | For PCSR/PCER   |
| PER9-122  | The dose due to a build-up of radionuclides in the environment has not been assessed during Step 1 or Step 2. | Use PC-CREAM 08 to make an assessment of whether the build-up of radionuclides in the local environment of the facility, based on the anticipated lifetime discharges, have the potential to prejudice legitimate users or uses of the land or sea.  | Before Site License Application, Environmental Permit Applications and/or Baseline 3 (BL3) Design Phase |

NEDO-34226 Revision C

| Action ID | Finding   | Forward Action  | Delivery Phase   |
|-----------|---|---|--|
| PER9-123  | The contribution to dose due to historical or future discharges from other nearby facilities has not been considered during Step 1 or Step 2.   | Consideration of historical and future discharges from other facilities in the locality.  | Before Site License Application, Environmental Permit Applications and/or BL3 Design Phase |
| PER9-124  | The IRAT2 tool used for Step 1 and Step 2 assesses dose for a coastal fishing family (liquid discharges) and a local resident family (gaseous discharges).  | Review and confirm the candidates for the representative person, including for direct radiation.  | For PCSR/PCER  |
| PER9-125  | Habit data has not been considered during the Step 1 and Step 2 prospective dose assessment.  | Use NRPB-W41 (Generalised habits data for radiological assessments) (Reference 9-44) to identify realistic habit data for the detailed dose assessment.<br>Use CEFAS radiological habits survey data for the site - specific dose assessment.                 | For PCSR/PCER  |
| PER9-126  | Food ingestion habits have not been considered during the Step 1 and Step 2 prospective dose assessment.  | Use NRPB-W41 (Generalised habits data for radiological assessments) and the 'top two' approach to generate realistic consumption data for the detailed dose assessment.<br>Use CEFAS radiological habits survey data for the site - specific dose assessment. | For PCSR/PCER  |
| PER9-127  | IRAT2 assumes Category D conditions (neutral stability, typically overcast) persist for 50% of the time. This is a conservative approach for most locations in the UK, since the assumed meteorological conditions over-represents those conditions that lead to the highest surface air concentrations when the source is at ground level. | Site-specific meteorological data will be required for the site-specific dose assessment.   | Before Site License Application, Environmental Permit Applications and/or BL3 Design Phase |



NEDO-34226 Revision C

| Action ID | Finding  | Forward Action  | Delivery Phase   |
|-----------|--|---|--|
| PER9-128  | The Step 1 and 2 dose assessment assumes a uniform windrose and that the local resident and terrestrial wildlife being located at 100 m from the release point for 100% of the time, and food produced at 500 m from the release point.  | Perform gaseous dispersion modelling using site - specific meteorological data to assess ground - level activity concentrations (Bq/m <sup>3</sup> ) and identify receptor locations.   | Before Site License Application, Environmental Permit Applications and/or BL3 Design Phase |
| PER6-203  | Step 2 assumed an effective stack height of 11.7 m is presented as the DRP, based on a release height of 35 m noting that the turbine building roof is at an elevation of approximately 31.5 m, which may not be the optimum stack height to ensure that public exposures to gaseous discharges are ALARA. The final design of the gaseous discharge stack will require site - specific data | <p>The future developer/operator shall determine the optimal Plant Vent Stack height and design to ensure that public exposures to gaseous discharges are ALARA. This will include:</p> <ul style="list-style-type: none"> <li>• Undertaking BAT assessments to support the design and location of the gaseous discharge system main stack when site-specific data become available. This will include consideration of meteorological conditions, topography, location of surrounding buildings, location of sensitive receptors, and the final site layout</li> <li>• Performing a stack height study using Atmospheric Dispersion Modeling Software (or equivalent) to identify the stack height above which benefits of improved dispersion from greater release height start to diminish</li> </ul> <p>Consideration of UK sampling and monitoring requirements for final discharge accountancy, including provision of laminar flow conditions for representative sampling, flow measurement requirements, and space/access requirements for independent sampling and monitoring by the regulator or their representative (see PER Ch E8)</p> | Before Site License Application, Environmental Permit Applications and/or BL3 Design Phase |

NEDO-34226 Revision C

| Action ID | Finding   | Forward Action   | Delivery Phase |
|-----------|---|--|----------------|
| PER9-130  | A simple and cautious assessment of exposure for NHS has been made using IRAT2.               | A more complex assessment of the dose to NHS should be performed using the ERICA tool.   | For PCSR/PCER  |
| PER9-131  | The uncertainty in the Step 1 and Step 2 prospective dose assessment has not been considered. | An assessment should be made of the uncertainty and variability associated with key assumptions for the detailed and site-specific dose assessments. | For PCSR/PCER  |